Current Build

4.3.2.16226 HL7 v3 Value Set ObservationType

Vocabulary Work Group Maturity Level: N/AExternal Use Context: Any

This value set (http://hl7.org/fhir/ValueSet/v3-ObservationType) is defined as part of HL7 v3. Related FHIR content: ObservationType.

Summary

Defining URL:http://hl7.org/fhir/ValueSet/v3-ObservationType
Name:ObservationType
Definition: Identifies the kinds of observations that can be performed
OID:2.16.840.1.113883.1.11.16226 (for OID based terminology systems)
Source ResourceXML / JSON

This value set is not currently used


This value set includes codes from the following code systems:

 

This expansion generated 10 Dec 2017


This value set has >1000 codes in it. In order to keep the publication size manageable, only a selection (1000 codes) of the whole set of codes is shown

CodeSystemDisplayDefinition
_ObservationTypehttp://hl7.org/fhir/v3/ActCodeObservationTypeIdentifies the kinds of observations that can be performed
_ActSpecObsCodehttp://hl7.org/fhir/v3/ActCodeActSpecObsCodeIdentifies the type of observation that is made about a specimen that may affect its processing, analysis or further result interpretation
ARTBLDhttp://hl7.org/fhir/v3/ActCodeActSpecObsArtBldCodeDescribes the artificial blood identifier that is associated with the specimen.
DILUTIONhttp://hl7.org/fhir/v3/ActCodeActSpecObsDilutionCodeAn observation that reports the dilution of a sample.
AUTO-HIGHhttp://hl7.org/fhir/v3/ActCodeAuto-High DilutionThe dilution of a sample performed by automated equipment. The value is specified by the equipment
AUTO-LOWhttp://hl7.org/fhir/v3/ActCodeAuto-Low DilutionThe dilution of a sample performed by automated equipment. The value is specified by the equipment
PREhttp://hl7.org/fhir/v3/ActCodePre-DilutionThe dilution of the specimen made prior to being loaded onto analytical equipment
RERUNhttp://hl7.org/fhir/v3/ActCodeRerun DilutionThe value of the dilution of a sample after it had been analyzed at a prior dilution value
EVNFCTShttp://hl7.org/fhir/v3/ActCodeActSpecObsEvntfctsCodeDomain provides codes that qualify the ActLabObsEnvfctsCode domain. (Environmental Factors)
INTFRhttp://hl7.org/fhir/v3/ActCodeActSpecObsInterferenceCodeAn observation that relates to factors that may potentially cause interference with the observation
FIBRINhttp://hl7.org/fhir/v3/ActCodeFibrinThe Fibrin Index of the specimen. In the case of only differentiating between Absent and Present, recommend using 0 and 1
HEMOLYSIShttp://hl7.org/fhir/v3/ActCodeHemolysisAn observation of the hemolysis index of the specimen in g/L
ICTERUShttp://hl7.org/fhir/v3/ActCodeIcterusAn observation that describes the icterus index of the specimen. It is recommended to use mMol/L of bilirubin
LIPEMIAhttp://hl7.org/fhir/v3/ActCodeLipemiaAn observation used to describe the Lipemia Index of the specimen. It is recommended to use the optical turbidity at 600 nm (in absorbance units).
VOLUMEhttp://hl7.org/fhir/v3/ActCodeActSpecObsVolumeCodeAn observation that reports the volume of a sample.
AVAILABLEhttp://hl7.org/fhir/v3/ActCodeAvailable VolumeThe available quantity of specimen. This is the current quantity minus any planned consumption (e.g., tests that are planned)
CONSUMPTIONhttp://hl7.org/fhir/v3/ActCodeConsumption VolumeThe quantity of specimen that is used each time the equipment uses this substance
CURRENThttp://hl7.org/fhir/v3/ActCodeCurrent VolumeThe current quantity of the specimen, i.e., initial quantity minus what has been actually used.
INITIALhttp://hl7.org/fhir/v3/ActCodeInitial VolumeThe initial quantity of the specimen in inventory
_AnnotationTypehttp://hl7.org/fhir/v3/ActCodeAnnotationTypeAnnotationType
_ActPatientAnnotationTypehttp://hl7.org/fhir/v3/ActCodeActPatientAnnotationTypeDescription:Provides a categorization for annotations recorded directly against the patient .
ANNDIhttp://hl7.org/fhir/v3/ActCodediagnostic image noteDescription:A note that is specific to a patient's diagnostic images, either historical, current or planned.
ANNGENhttp://hl7.org/fhir/v3/ActCodegeneral noteDescription:A general or uncategorized note.
ANNIMMhttp://hl7.org/fhir/v3/ActCodeimmunization noteA note that is specific to a patient's immunizations, either historical, current or planned.
ANNLABhttp://hl7.org/fhir/v3/ActCodelaboratory noteDescription:A note that is specific to a patient's laboratory results, either historical, current or planned.
ANNMEDhttp://hl7.org/fhir/v3/ActCodemedication noteDescription:A note that is specific to a patient's medications, either historical, current or planned.
_GeneticObservationTypehttp://hl7.org/fhir/v3/ActCodeGeneticObservationTypeDescription: None provided
GENEhttp://hl7.org/fhir/v3/ActCodegeneDescription: A DNA segment that contributes to phenotype/function. In the absence of demonstrated function a gene may be characterized by sequence, transcription or homology
_ImmunizationObservationTypehttp://hl7.org/fhir/v3/ActCodeImmunizationObservationTypeDescription: Observation codes which describe characteristics of the immunization material.
OBSANTChttp://hl7.org/fhir/v3/ActCodeantigen countDescription: Indicates the valid antigen count.
OBSANTVhttp://hl7.org/fhir/v3/ActCodeantigen validityDescription: Indicates whether an antigen is valid or invalid.
_IndividualCaseSafetyReportTypehttp://hl7.org/fhir/v3/ActCodeIndividual Case Safety Report TypeA code that is used to indicate the type of case safety report received from sender. The current code example reference is from the International Conference on Harmonisation (ICH) Expert Workgroup guideline on Clinical Safety Data Management: Data Elements for Transmission of Individual Case Safety Reports. The unknown/unavailable option allows the transmission of information from a secondary sender where the initial sender did not specify the type of report. Example concepts include: Spontaneous, Report from study, Other.
PAT_ADV_EVNThttp://hl7.org/fhir/v3/ActCodepatient adverse eventIndicates that the ICSR is describing problems that a patient experienced after receiving a vaccine product.
VAC_PROBLEMhttp://hl7.org/fhir/v3/ActCodevaccine product problemIndicates that the ICSR is describing a problem with the actual vaccine product such as physical defects (cloudy, particulate matter) or inability to confer immunity.
_LOINCObservationActContextAgeTypehttp://hl7.org/fhir/v3/ActCodeLOINCObservationActContextAgeTypeDefinition:The set of LOINC codes for the act of determining the period of time that has elapsed since an entity was born or created.
21611-9http://hl7.org/fhir/v3/ActCodeage patient qn estDefinition:Estimated age.
21612-7http://hl7.org/fhir/v3/ActCodeage patient qn reportedDefinition:Reported age.
29553-5http://hl7.org/fhir/v3/ActCodeage patient qn calcDefinition:Calculated age.
30525-0http://hl7.org/fhir/v3/ActCodeage patient qn definitionDefinition:General specification of age with no implied method of determination.
30972-4http://hl7.org/fhir/v3/ActCodeage at onset of adverse eventDefinition:Age at onset of associated adverse event; no implied method of determination.
_MedicationObservationTypehttp://hl7.org/fhir/v3/ActCodeMedicationObservationTypeMedicationObservationType
REP_HALF_LIFEhttp://hl7.org/fhir/v3/ActCoderepresentative half-lifeDescription:This observation represents an 'average' or 'expected' half-life typical of the product.
SPLCOATINGhttp://hl7.org/fhir/v3/ActCodecoatingDefinition: A characteristic of an oral solid dosage form of a medicinal product, indicating whether it has one or more coatings such as sugar coating, film coating, or enteric coating. Only coatings to the external surface or the dosage form should be considered (for example, coatings to individual pellets or granules inside a capsule or tablet are excluded from consideration). Constraints: The Observation.value must be a Boolean (BL) with true for the presence or false for the absence of one or more coatings on a solid dosage form.
SPLCOLORhttp://hl7.org/fhir/v3/ActCodecolorDefinition: A characteristic of an oral solid dosage form of a medicinal product, specifying the color or colors that most predominantly define the appearance of the dose form. SPLCOLOR is not an FDA specification for the actual color of solid dosage forms or the names of colors that can appear in labeling. Constraints: The Observation.value must be a single coded value or a list of multiple coded values, specifying one or more distinct colors that approximate of the color(s) of distinct areas of the solid dosage form, such as the different sides of a tablet or one-part capsule, or the different halves of a two-part capsule. Bands on banded capsules, regardless of the color, are not considered when assigning an SPLCOLOR. Imprints on the dosage form, regardless of their color are not considered when assigning an SPLCOLOR. If more than one color exists on a particular side or half, then the most predominant color on that side or half is recorded. If the gelatin capsule shell is colorless and transparent, use the predominant color of the contents that appears through the colorless and transparent capsule shell. Colors can include: Black;Gray;White;Red;Pink;Purple;Green;Yellow;Orange;Brown;Blue;Turquoise.
SPLIMAGEhttp://hl7.org/fhir/v3/ActCodeimageDescription: A characteristic representing a single file reference that contains two or more views of the same dosage form of the product; in most cases this should represent front and back views of the dosage form, but occasionally additional views might be needed in order to capture all of the important physical characteristics of the dosage form. Any imprint and/or symbol should be clearly identifiable, and the viewer should not normally need to rotate the image in order to read it. Images that are submitted with SPL should be included in the same directory as the SPL file.
SPLIMPRINThttp://hl7.org/fhir/v3/ActCodeimprintDefinition: A characteristic of an oral solid dosage form of a medicinal product, specifying the alphanumeric text that appears on the solid dosage form, including text that is embossed, debossed, engraved or printed with ink. The presence of other non-textual distinguishing marks or symbols is recorded by SPLSYMBOL. Examples: Included in SPLIMPRINT are alphanumeric text that appears on the bands of banded capsules and logos and other symbols that can be interpreted as letters or numbers. Constraints: The Observation.value must be of type Character String (ST). Excluded from SPLIMPRINT are internal and external cut-outs in the form of alphanumeric text and the letter 'R' with a circle around it (when referring to a registered trademark) and the letters 'TM' (when referring to a 'trade mark'). To record text, begin on either side or part of the dosage form. Start at the top left and progress as one would normally read a book. Enter a semicolon to show separation between words or line divisions.
SPLSCORINGhttp://hl7.org/fhir/v3/ActCodescoringDefinition: A characteristic of an oral solid dosage form of a medicinal product, specifying the number of equal pieces that the solid dosage form can be divided into using score line(s). Example: One score line creating two equal pieces is given a value of 2, two parallel score lines creating three equal pieces is given a value of 3. Constraints: Whether three parallel score lines create four equal pieces or two intersecting score lines create two equal pieces using one score line and four equal pieces using both score lines, both have the scoring value of 4. Solid dosage forms that are not scored are given a value of 1. Solid dosage forms that can only be divided into unequal pieces are given a null-value with nullFlavor other (OTH).
SPLSHAPEhttp://hl7.org/fhir/v3/ActCodeshapeDescription: A characteristic of an oral solid dosage form of a medicinal product, specifying the two dimensional representation of the solid dose form, in terms of the outside perimeter of a solid dosage form when the dosage form, resting on a flat surface, is viewed from directly above, including slight rounding of corners. SPLSHAPE does not include embossing, scoring, debossing, or internal cut-outs. SPLSHAPE is independent of the orientation of the imprint and logo. Shapes can include: Triangle (3 sided); Square; Round; Semicircle; Pentagon (5 sided); Diamond; Double circle; Bullet; Hexagon (6 sided); Rectangle; Gear; Capsule; Heptagon (7 sided); Trapezoid; Oval; Clover; Octagon (8 sided); Tear; Freeform.
SPLSIZEhttp://hl7.org/fhir/v3/ActCodesizeDefinition: A characteristic of an oral solid dosage form of a medicinal product, specifying the longest single dimension of the solid dosage form as a physical quantity in the dimension of length (e.g., 3 mm). The length is should be specified in millimeters and should be rounded to the nearest whole millimeter. Example: SPLSIZE for a rectangular shaped tablet is the length and SPLSIZE for a round shaped tablet is the diameter.
SPLSYMBOLhttp://hl7.org/fhir/v3/ActCodesymbolDefinition: A characteristic of an oral solid dosage form of a medicinal product, to describe whether or not the medicinal product has a mark or symbol appearing on it for easy and definite recognition. Score lines, letters, numbers, and internal and external cut-outs are not considered marks or symbols. See SPLSCORING and SPLIMPRINT for these characteristics. Constraints: The Observation.value must be a Boolean (BL) with <u>true</u> indicating the presence and <u>false</u> for the absence of marks or symbols. Example:
_ObservationIssueTriggerCodedObservationTypehttp://hl7.org/fhir/v3/ActCodeObservationIssueTriggerCodedObservationTypeDistinguishes the kinds of coded observations that could be the trigger for clinical issue detection. These are observations that are not measurable, but instead can be defined with codes. Coded observation types include: Allergy, Intolerance, Medical Condition, Pregnancy status, etc.
_CaseTransmissionModehttp://hl7.org/fhir/v3/ActCodecase transmission modeCode for the mechanism by which disease was acquired by the living subject involved in the public health case. Includes sexually transmitted, airborne, bloodborne, vectorborne, foodborne, zoonotic, nosocomial, mechanical, dermal, congenital, environmental exposure, indeterminate.
AIRTRNShttp://hl7.org/fhir/v3/ActCodeairborne transmissionCommunication of an agent from a living subject or environmental source to a living subject through indirect contact via oral or nasal inhalation.
ANANTRNShttp://hl7.org/fhir/v3/ActCodeanimal to animal transmissionCommunication of an agent from one animal to another proximate animal.
ANHUMTRNShttp://hl7.org/fhir/v3/ActCodeanimal to human transmissionCommunication of an agent from an animal to a proximate person.
BDYFLDTRNShttp://hl7.org/fhir/v3/ActCodebody fluid contact transmissionCommunication of an agent from one living subject to another living subject through direct contact with any body fluid.
BLDTRNShttp://hl7.org/fhir/v3/ActCodeblood borne transmissionCommunication of an agent to a living subject through direct contact with blood or blood products whether the contact with blood is part of a therapeutic procedure or not.
DERMTRNShttp://hl7.org/fhir/v3/ActCodetransdermal transmissionCommunication of an agent from a living subject or environmental source to a living subject via agent migration through intact skin.
ENVTRNShttp://hl7.org/fhir/v3/ActCodeenvironmental exposure transmissionCommunication of an agent from an environmental surface or source to a living subject by direct contact.
FECTRNShttp://hl7.org/fhir/v3/ActCodefecal-oral transmissionCommunication of an agent from a living subject or environmental source to a living subject through oral contact with material contaminated by person or animal fecal material.
FOMTRNShttp://hl7.org/fhir/v3/ActCodefomite transmissionCommunication of an agent from an non-living material to a living subject through direct contact.
FOODTRNShttp://hl7.org/fhir/v3/ActCodefood-borne transmissionCommunication of an agent from a food source to a living subject via oral consumption.
HUMHUMTRNShttp://hl7.org/fhir/v3/ActCodehuman to human transmissionCommunication of an agent from a person to a proximate person.
INDTRNShttp://hl7.org/fhir/v3/ActCodeindeterminate disease transmission modeCommunication of an agent to a living subject via an undetermined route.
LACTTRNShttp://hl7.org/fhir/v3/ActCodelactation transmissionCommunication of an agent from one living subject to another living subject through direct contact with mammalian milk or colostrum.
NOSTRNShttp://hl7.org/fhir/v3/ActCodenosocomial transmissionCommunication of an agent from any entity to a living subject while the living subject is in the patient role in a healthcare facility.
PARTRNShttp://hl7.org/fhir/v3/ActCodeparenteral transmissionCommunication of an agent from a living subject or environmental source to a living subject where the acquisition of the agent is not via the alimentary canal.
PLACTRNShttp://hl7.org/fhir/v3/ActCodetransplacental transmissionCommunication of an agent from a living subject to the progeny of that living subject via agent migration across the maternal-fetal placental membranes while in utero.
SEXTRNShttp://hl7.org/fhir/v3/ActCodesexual transmissionCommunication of an agent from one living subject to another living subject through direct contact with genital or oral tissues as part of a sexual act.
TRNSFTRNShttp://hl7.org/fhir/v3/ActCodetransfusion transmissionCommunication of an agent from one living subject to another living subject through direct contact with blood or blood products where the contact with blood is part of a therapeutic procedure.
VECTRNShttp://hl7.org/fhir/v3/ActCodevector-borne transmissionCommunication of an agent from a living subject acting as a required intermediary in the agent transmission process to a recipient living subject via direct contact.
WATTRNShttp://hl7.org/fhir/v3/ActCodewater-borne transmissionCommunication of an agent from a contaminated water source to a living subject whether the water is ingested as a food or not. The route of entry of the water may be through any bodily orifice.
_ObservationQualityMeasureAttributehttp://hl7.org/fhir/v3/ActCodeObservationQualityMeasureAttributeCodes used to define various metadata aspects of a health quality measure.
AGGREGATEhttp://hl7.org/fhir/v3/ActCodeaggregate measure observationIndicates that the observation is carrying out an aggregation calculation, contained in the value element.
CMPMSRMTHhttp://hl7.org/fhir/v3/ActCodecomposite measure methodIndicates what method is used in a quality measure to combine the component measure results included in an composite measure.
CMPMSRSCRWGHThttp://hl7.org/fhir/v3/ActCodecomponent measure scoring weightAn attribute of a quality measure describing the weight this component measure score is to carry in determining the overall composite measure final score. The value is real value greater than 0 and less than 1.0. Each component measure score will be multiplied by its CMPMSRSCRWGHT and then summed with the other component measures to determine the final overall composite measure score. The sum across all CMPMSRSCRWGHT values within a single composite measure SHALL be 1.0. The value assigned is scoped to the composite measure referencing this component measure only.
COPYhttp://hl7.org/fhir/v3/ActCodecopyrightIdentifies the organization(s) who own the intellectual property represented by the eMeasure.
CRShttp://hl7.org/fhir/v3/ActCodeclinical recommendation statementSummary of relevant clinical guidelines or other clinical recommendations supporting this eMeasure.
DEFhttp://hl7.org/fhir/v3/ActCodedefinitionDescription of individual terms, provided as needed.
DISChttp://hl7.org/fhir/v3/ActCodedisclaimerDisclaimer information for the eMeasure.
FINALDThttp://hl7.org/fhir/v3/ActCodefinalized date/timeThe timestamp when the eMeasure was last packaged in the Measure Authoring Tool.
GUIDEhttp://hl7.org/fhir/v3/ActCodeguidanceUsed to allow measure developers to provide additional guidance for implementers to understand greater specificity than could be provided in the logic for data criteria.
IDURhttp://hl7.org/fhir/v3/ActCodeimprovement notationInformation on whether an increase or decrease in score is the preferred result (e.g., a higher score indicates better quality OR a lower score indicates better quality OR quality is within a range).
ITMCNThttp://hl7.org/fhir/v3/ActCodeitems countedDescribes the items counted by the measure (e.g., patients, encounters, procedures, etc.)
KEYhttp://hl7.org/fhir/v3/ActCodekeywordA significant word that aids in discoverability.
MEDThttp://hl7.org/fhir/v3/ActCodemeasurement end dateThe end date of the measurement period.
MSDhttp://hl7.org/fhir/v3/ActCodemeasurement start dateThe start date of the measurement period.
MSRADJhttp://hl7.org/fhir/v3/ActCoderisk adjustmentThe method of adjusting for clinical severity and conditions present at the start of care that can influence patient outcomes for making valid comparisons of outcome measures across providers. Indicates whether an eMeasure is subject to the statistical process for reducing, removing, or clarifying the influences of confounding factors to allow more useful comparisons.
MSRAGGhttp://hl7.org/fhir/v3/ActCoderate aggregationDescribes how to combine information calculated based on logic in each of several populations into one summarized result. It can also be used to describe how to risk adjust the data based on supplemental data elements described in the eMeasure. (e.g., pneumonia hospital measures antibiotic selection in the ICU versus non-ICU and then the roll-up of the two). Open Issue: The description does NOT align well with the definition used in the HQMF specfication; correct the MSGAGG definition, and the possible distinction of MSRAGG as a child of AGGREGATE.
MSRIMPROVhttp://hl7.org/fhir/v3/ActCodehealth quality measure improvement notationInformation on whether an increase or decrease in score is the preferred result. This should reflect information on which way is better, an increase or decrease in score.
MSRJURhttp://hl7.org/fhir/v3/ActCodejurisdictionThe list of jurisdiction(s) for which the measure applies.
MSRRPTRhttp://hl7.org/fhir/v3/ActCodereporter typeType of person or organization that is expected to report the issue.
MSRRPTTIMEhttp://hl7.org/fhir/v3/ActCodetimeframe for reportingThe maximum time that may elapse following completion of the measure until the measure report must be sent to the receiver.
MSRSCOREhttp://hl7.org/fhir/v3/ActCodemeasure scoringIndicates how the calculation is performed for the eMeasure (e.g., proportion, continuous variable, ratio)
MSRSEThttp://hl7.org/fhir/v3/ActCodehealth quality measure care settingLocation(s) in which care being measured is rendered Usage Note: MSRSET is used rather than RoleCode because the setting applies to what is being measured, as opposed to participating directly in the health quality measure documantion itself).
MSRTOPIChttp://hl7.org/fhir/v3/ActCodehealth quality measure topic typehealth quality measure topic type
MSRTPhttp://hl7.org/fhir/v3/ActCodemeasurement periodThe time period for which the eMeasure applies.
MSRTYPEhttp://hl7.org/fhir/v3/ActCodemeasure typeIndicates whether the eMeasure is used to examine a process or an outcome over time (e.g., Structure, Process, Outcome).
RAThttp://hl7.org/fhir/v3/ActCoderationaleSuccinct statement of the need for the measure. Usually includes statements pertaining to Importance criterion: impact, gap in care and evidence.
REFhttp://hl7.org/fhir/v3/ActCodereferenceIdentifies bibliographic citations or references to clinical practice guidelines, sources of evidence, or other relevant materials supporting the intent and rationale of the eMeasure.
SDEhttp://hl7.org/fhir/v3/ActCodesupplemental data elementsComparison of results across strata can be used to show where disparities exist or where there is a need to expose differences in results. For example, Centers for Medicare & Medicaid Services (CMS) in the U.S. defines four required Supplemental Data Elements (payer, ethnicity, race, and gender), which are variables used to aggregate data into various subgroups. Additional supplemental data elements required for risk adjustment or other purposes of data aggregation can be included in the Supplemental Data Element section.
STRAThttp://hl7.org/fhir/v3/ActCodestratificationDescribes the strata for which the measure is to be evaluated. There are three examples of reasons for stratification based on existing work. These include: (1) evaluate the measure based on different age groupings within the population described in the measure (e.g., evaluate the whole [age 14-25] and each sub-stratum [14-19] and [20-25]); (2) evaluate the eMeasure based on either a specific condition, a specific discharge location, or both; (3) evaluate the eMeasure based on different locations within a facility (e.g., evaluate the overall rate for all intensive care units and also some strata include additional findings [specific birth weights for neonatal intensive care units]).
TRANFhttp://hl7.org/fhir/v3/ActCodetransmission formatCan be a URL or hyperlinks that link to the transmission formats that are specified for a particular reporting program.
USEhttp://hl7.org/fhir/v3/ActCodenotice of useUsage notes.
_ObservationSequenceTypehttp://hl7.org/fhir/v3/ActCodeObservationSequenceTypeObservationSequenceType
TIME_ABSOLUTEhttp://hl7.org/fhir/v3/ActCodeabsolute time sequenceA sequence of values in the "absolute" time domain. This is the same time domain that all HL7 timestamps use. It is time as measured by the Gregorian calendar
TIME_RELATIVEhttp://hl7.org/fhir/v3/ActCoderelative time sequenceA sequence of values in a "relative" time domain. The time is measured relative to the earliest effective time in the Observation Series containing this sequence.
_ObservationSeriesTypehttp://hl7.org/fhir/v3/ActCodeObservationSeriesTypeObservationSeriesType
_ECGObservationSeriesTypehttp://hl7.org/fhir/v3/ActCodeECGObservationSeriesTypeECGObservationSeriesType
REPRESENTATIVE_BEAThttp://hl7.org/fhir/v3/ActCodeECG representative beat waveformsThis Observation Series type contains waveforms of a "representative beat" (a.k.a. "median beat" or "average beat"). The waveform samples are measured in relative time, relative to the beginning of the beat as defined by the Observation Series effective time. The waveforms are not directly acquired from the subject, but rather algorithmically derived from the "rhythm" waveforms.
RHYTHMhttp://hl7.org/fhir/v3/ActCodeECG rhythm waveformsThis Observation type contains ECG "rhythm" waveforms. The waveform samples are measured in absolute time (a.k.a. "subject time" or "effective time"). These waveforms are usually "raw" with some minimal amount of noise reduction and baseline filtering applied.
_PatientImmunizationRelatedObservationTypehttp://hl7.org/fhir/v3/ActCodePatientImmunizationRelatedObservationTypeDescription: Reporting codes that are related to an immunization event.
CLSSRMhttp://hl7.org/fhir/v3/ActCodeclassroomDescription: The class room associated with the patient during the immunization event.
GRADEhttp://hl7.org/fhir/v3/ActCodegradeDescription: The school grade or level the patient was in when immunized.
SCHLhttp://hl7.org/fhir/v3/ActCodeschoolDescription: The school the patient attended when immunized.
SCHLDIVhttp://hl7.org/fhir/v3/ActCodeschool divisionDescription: The school division or district associated with the patient during the immunization event.
TEACHERhttp://hl7.org/fhir/v3/ActCodeteacherDescription: The patient's teacher when immunized.
_PopulationInclusionObservationTypehttp://hl7.org/fhir/v3/ActCodePopulationInclusionObservationTypeObservation types for specifying criteria used to assert that a subject is included in a particular population.
DENEXhttp://hl7.org/fhir/v3/ActCodedenominator exclusionsCriteria which specify subjects who should be removed from the eMeasure population and denominator before determining if numerator criteria are met. Denominator exclusions are used in proportion and ratio measures to help narrow the denominator.
DENEXCEPhttp://hl7.org/fhir/v3/ActCodedenominator exceptionsCriteria which specify the removal of a subject, procedure or unit of measurement from the denominator, only if the numerator criteria are not met. Denominator exceptions allow for adjustment of the calculated score for those providers with higher risk populations. Denominator exceptions are used only in proportion eMeasures. They are not appropriate for ratio or continuous variable eMeasures. Denominator exceptions allow for the exercise of clinical judgment and should be specifically defined where capturing the information in a structured manner fits the clinical workflow. Generic denominator exception reasons used in proportion eMeasures fall into three general categories: Medical reasons Patient (or subject) reasons System reasons
DENOMhttp://hl7.org/fhir/v3/ActCodedenominatorCriteria for specifying the entities to be evaluated by a specific quality measure, based on a shared common set of characteristics (within a specific measurement set to which a given measure belongs). The denominator can be the same as the initial population, or it may be a subset of the initial population to further constrain it for the purpose of the eMeasure. Different measures within an eMeasure set may have different denominators. Continuous Variable eMeasures do not have a denominator, but instead define a measure population.
IPOPhttp://hl7.org/fhir/v3/ActCodeinitial populationCriteria for specifying the entities to be evaluated by a specific quality measure, based on a shared common set of characteristics (within a specific measurement set to which a given measure belongs).
IPPOPhttp://hl7.org/fhir/v3/ActCodeinitial patient populationCriteria for specifying the patients to be evaluated by a specific quality measure, based on a shared common set of characteristics (within a specific measurement set to which a given measure belongs). Details often include information based upon specific age groups, diagnoses, diagnostic and procedure codes, and enrollment periods.
MSRPOPLhttp://hl7.org/fhir/v3/ActCodemeasure populationCriteria for specifying the measure population as a narrative description (e.g., all patients seen in the Emergency Department during the measurement period). This is used only in continuous variable eMeasures.
MSRPOPLEXhttp://hl7.org/fhir/v3/ActCodemeasure population exclusionsCriteria for specifying subjects who should be removed from the eMeasure's Initial Population and Measure Population. Measure Population Exclusions are used in Continuous Variable measures to help narrow the Measure Population before determining the value(s) of the continuous variable(s).
NUMERhttp://hl7.org/fhir/v3/ActCodenumeratorCriteria for specifying the processes or outcomes expected for each patient, procedure, or other unit of measurement defined in the denominator for proportion measures, or related to (but not directly derived from) the denominator for ratio measures (e.g., a numerator listing the number of central line blood stream infections and a denominator indicating the days per thousand of central line usage in a specific time period).
NUMEXhttp://hl7.org/fhir/v3/ActCodenumerator exclusionsCriteria for specifying instances that should not be included in the numerator data. (e.g., if the number of central line blood stream infections per 1000 catheter days were to exclude infections with a specific bacterium, that bacterium would be listed as a numerator exclusion). Numerator Exclusions are used only in ratio eMeasures.
_PreferenceObservationTypehttp://hl7.org/fhir/v3/ActCode_PreferenceObservationTypeTypes of observations that can be made about Preferences.
PREFSTRENGTHhttp://hl7.org/fhir/v3/ActCodepreference strengthAn observation about how important a preference is to the target of the preference.
ADVERSE_REACTIONhttp://hl7.org/fhir/v3/ActCodeAdverse ReactionIndicates that the observation is of an unexpected negative occurrence in the subject suspected to result from the subject's exposure to one or more agents. Observation values would be the symptom resulting from the reaction.
ASSERTIONhttp://hl7.org/fhir/v3/ActCodeAssertionDescription:Refines classCode OBS to indicate an observation in which observation.value contains a finding or other nominalized statement, where the encoded information in Observation.value is not altered by Observation.code. For instance, observation.code="ASSERTION" and observation.value="fracture of femur present" is an assertion of a clinical finding of femur fracture.
CASESERhttp://hl7.org/fhir/v3/ActCodecase seriousness criteriaDefinition:An observation that provides a characterization of the level of harm to an investigation subject as a result of a reaction or event.
CDIOhttp://hl7.org/fhir/v3/ActCodecase disease imported observationAn observation that states whether the disease was likely acquired outside the jurisdiction of observation, and if so, the nature of the inter-jurisdictional relationship. OpenIssue: This code could be moved to LOINC if it can be done before there are significant implemenations using it.
CRIThttp://hl7.org/fhir/v3/ActCodecriticalityA clinical judgment as to the worst case result of a future exposure (including substance administration). When the worst case result is assessed to have a life-threatening or organ system threatening potential, it is considered to be of high criticality.
CTMOhttp://hl7.org/fhir/v3/ActCodecase transmission mode observationAn observation that states the mechanism by which disease was acquired by the living subject involved in the public health case. OpenIssue: This code could be moved to LOINC if it can be done before there are significant implemenations using it.
DXhttp://hl7.org/fhir/v3/ActCodeObservationDiagnosisTypesIncludes all codes defining types of indications such as diagnosis, symptom and other indications such as contrast agents for lab tests.
ADMDXhttp://hl7.org/fhir/v3/ActCodeadmitting diagnosisAdmitting diagnosis are the diagnoses documented for administrative purposes as the basis for a hospital admission.
DISDXhttp://hl7.org/fhir/v3/ActCodedischarge diagnosisDischarge diagnosis are the diagnoses documented for administrative purposes as the time of hospital discharge.
INTDXhttp://hl7.org/fhir/v3/ActCodeintermediate diagnosisIntermediate diagnoses are those diagnoses documented for administrative purposes during the course of a hospital stay.
NOIhttp://hl7.org/fhir/v3/ActCodenature of injuryThe type of injury that the injury coding specifies.
GISTIERhttp://hl7.org/fhir/v3/ActCodeGIS tierDescription: Accuracy determined as per the GIS tier code system.
HHOBShttp://hl7.org/fhir/v3/ActCodehousehold situation observationIndicates that the observation is of a person’s living situation in a household including the household composition and circumstances.
ISSUEhttp://hl7.org/fhir/v3/ActCodedetected issueThere is a clinical issue for the therapy that makes continuation of the therapy inappropriate. Open Issue: The definition of this code does not correctly represent the concept space of its specializations (children)
_ActAdministrativeDetectedIssueCodehttp://hl7.org/fhir/v3/ActCodeActAdministrativeDetectedIssueCodeIdentifies types of detectyed issues for Act class "ALRT" for the administrative and patient administrative acts domains.
_ActAdministrativeAuthorizationDetectedIssueCodehttp://hl7.org/fhir/v3/ActCodeActAdministrativeAuthorizationDetectedIssueCodeActAdministrativeAuthorizationDetectedIssueCode
NAThttp://hl7.org/fhir/v3/ActCodeInsufficient authorizationThe requesting party has insufficient authorization to invoke the interaction.
SUPPRESSEDhttp://hl7.org/fhir/v3/ActCoderecord suppressedDescription: One or more records in the query response have been suppressed due to consent or privacy restrictions.
VALIDAThttp://hl7.org/fhir/v3/ActCodevalidation issueDescription:The specified element did not pass business-rule validation.
KEY204http://hl7.org/fhir/v3/ActCodeUnknown key identifierThe ID of the patient, order, etc., was not found. Used for transactions other than additions, e.g. transfer of a non-existent patient.
KEY205http://hl7.org/fhir/v3/ActCodeDuplicate key identifierThe ID of the patient, order, etc., already exists. Used in response to addition transactions (Admit, New Order, etc.).
COMPLYhttp://hl7.org/fhir/v3/ActCodeCompliance AlertThere may be an issue with the patient complying with the intentions of the proposed therapy
DUPTHPYhttp://hl7.org/fhir/v3/ActCodeDuplicate Therapy AlertThe proposed therapy appears to duplicate an existing therapy
DUPTHPCLShttp://hl7.org/fhir/v3/ActCodeduplicate therapeutic alass alertDescription:The proposed therapy appears to have the same intended therapeutic benefit as an existing therapy, though the specific mechanisms of action vary.
DUPTHPGENhttp://hl7.org/fhir/v3/ActCodeduplicate generic alertDescription:The proposed therapy appears to have the same intended therapeutic benefit as an existing therapy and uses the same mechanisms of action as the existing therapy.
ABUSEhttp://hl7.org/fhir/v3/ActCodecommonly abused/misused alertDescription:The proposed therapy is frequently misused or abused and therefore should be used with caution and/or monitoring.
FRAUDhttp://hl7.org/fhir/v3/ActCodepotential fraudDescription:The request is suspected to have a fraudulent basis.
PLYDOChttp://hl7.org/fhir/v3/ActCodePoly-orderer AlertA similar or identical therapy was recently ordered by a different practitioner.
PLYPHRMhttp://hl7.org/fhir/v3/ActCodePoly-supplier AlertThis patient was recently supplied a similar or identical therapy from a different pharmacy or supplier.
DOSEhttp://hl7.org/fhir/v3/ActCodeDosage problemProposed dosage instructions for therapy differ from standard practice.
DOSECONDhttp://hl7.org/fhir/v3/ActCodedosage-condition alertDescription:Proposed dosage is inappropriate due to patient's medical condition.
DOSEDURhttp://hl7.org/fhir/v3/ActCodeDose-Duration AlertProposed length of therapy differs from standard practice.
DOSEDURHhttp://hl7.org/fhir/v3/ActCodeDose-Duration High AlertProposed length of therapy is longer than standard practice
DOSEDURHINDhttp://hl7.org/fhir/v3/ActCodeDose-Duration High for Indication AlertProposed length of therapy is longer than standard practice for the identified indication or diagnosis
DOSEDURLhttp://hl7.org/fhir/v3/ActCodeDose-Duration Low AlertProposed length of therapy is shorter than that necessary for therapeutic effect
DOSEDURLINDhttp://hl7.org/fhir/v3/ActCodeDose-Duration Low for Indication AlertProposed length of therapy is shorter than standard practice for the identified indication or diagnosis
DOSEHhttp://hl7.org/fhir/v3/ActCodeHigh Dose AlertProposed dosage exceeds standard practice
DOSEHINDAhttp://hl7.org/fhir/v3/ActCodeHigh Dose for Age AlertProposed dosage exceeds standard practice for the patient's age
DOSEHINDhttp://hl7.org/fhir/v3/ActCodeHigh Dose for Indication AlertHigh Dose for Indication Alert
DOSEHINDSAhttp://hl7.org/fhir/v3/ActCodeHigh Dose for Height/Surface Area AlertProposed dosage exceeds standard practice for the patient's height or body surface area
DOSEHINDWhttp://hl7.org/fhir/v3/ActCodeHigh Dose for Weight AlertProposed dosage exceeds standard practice for the patient's weight
DOSEIVLhttp://hl7.org/fhir/v3/ActCodeDose-Interval AlertProposed dosage interval/timing differs from standard practice
DOSEIVLINDhttp://hl7.org/fhir/v3/ActCodeDose-Interval for Indication AlertProposed dosage interval/timing differs from standard practice for the identified indication or diagnosis
DOSELhttp://hl7.org/fhir/v3/ActCodeLow Dose AlertProposed dosage is below suggested therapeutic levels
DOSELINDAhttp://hl7.org/fhir/v3/ActCodeLow Dose for Age AlertProposed dosage is below suggested therapeutic levels for the patient's age
DOSELINDhttp://hl7.org/fhir/v3/ActCodeLow Dose for Indication AlertLow Dose for Indication Alert
DOSELINDSAhttp://hl7.org/fhir/v3/ActCodeLow Dose for Height/Surface Area AlertProposed dosage is below suggested therapeutic levels for the patient's height or body surface area
DOSELINDWhttp://hl7.org/fhir/v3/ActCodeLow Dose for Weight AlertProposed dosage is below suggested therapeutic levels for the patient's weight
MDOSEhttp://hl7.org/fhir/v3/ActCodemaximum dosage reachedDescription:The maximum quantity of this drug allowed to be administered within a particular time-range (month, year, lifetime) has been reached or exceeded.
OBSAhttp://hl7.org/fhir/v3/ActCodeObservation AlertProposed therapy may be inappropriate or contraindicated due to conditions or characteristics of the patient
AGEhttp://hl7.org/fhir/v3/ActCodeAge AlertProposed therapy may be inappropriate or contraindicated due to patient age
ADALRThttp://hl7.org/fhir/v3/ActCodeadult alertProposed therapy is outside of the standard practice for an adult patient.
GEALRThttp://hl7.org/fhir/v3/ActCodegeriatric alertProposed therapy is outside of standard practice for a geriatric patient.
PEALRThttp://hl7.org/fhir/v3/ActCodepediatric alertProposed therapy is outside of the standard practice for a pediatric patient.
CONDhttp://hl7.org/fhir/v3/ActCodeCondition AlertProposed therapy may be inappropriate or contraindicated due to an existing/recent patient condition or diagnosis
HGHThttp://hl7.org/fhir/v3/ActCodeHGHT
LACThttp://hl7.org/fhir/v3/ActCodeLactation AlertProposed therapy may be inappropriate or contraindicated when breast-feeding
PREGhttp://hl7.org/fhir/v3/ActCodePregnancy AlertProposed therapy may be inappropriate or contraindicated during pregnancy
WGHThttp://hl7.org/fhir/v3/ActCodeWGHT
CREACThttp://hl7.org/fhir/v3/ActCodecommon reaction alertDescription:Proposed therapy may be inappropriate or contraindicated because of a common but non-patient specific reaction to the product. Example:There is no record of a specific sensitivity for the patient, but the presence of the sensitivity is common and therefore caution is warranted.
GENhttp://hl7.org/fhir/v3/ActCodeGenetic AlertProposed therapy may be inappropriate or contraindicated due to patient genetic indicators.
GENDhttp://hl7.org/fhir/v3/ActCodeGender AlertProposed therapy may be inappropriate or contraindicated due to patient gender.
LABhttp://hl7.org/fhir/v3/ActCodeLab AlertProposed therapy may be inappropriate or contraindicated due to recent lab test results
REACThttp://hl7.org/fhir/v3/ActCodeReaction AlertProposed therapy may be inappropriate or contraindicated based on the potential for a patient reaction to the proposed product
ALGYhttp://hl7.org/fhir/v3/ActCodeAllergy AlertProposed therapy may be inappropriate or contraindicated because of a recorded patient allergy to the proposed product. (Allergies are immune based reactions.)
INThttp://hl7.org/fhir/v3/ActCodeIntolerance AlertProposed therapy may be inappropriate or contraindicated because of a recorded patient intolerance to the proposed product. (Intolerances are non-immune based sensitivities.)
RREACThttp://hl7.org/fhir/v3/ActCodeRelated Reaction AlertProposed therapy may be inappropriate or contraindicated because of a potential patient reaction to a cross-sensitivity related product.
RALGhttp://hl7.org/fhir/v3/ActCodeRelated Allergy AlertProposed therapy may be inappropriate or contraindicated because of a recorded patient allergy to a cross-sensitivity related product. (Allergies are immune based reactions.)
RARhttp://hl7.org/fhir/v3/ActCodeRelated Prior Reaction AlertProposed therapy may be inappropriate or contraindicated because of a recorded prior adverse reaction to a cross-sensitivity related product.
RINThttp://hl7.org/fhir/v3/ActCodeRelated Intolerance AlertProposed therapy may be inappropriate or contraindicated because of a recorded patient intolerance to a cross-sensitivity related product. (Intolerances are non-immune based sensitivities.)
BUShttp://hl7.org/fhir/v3/ActCodebusiness constraint violationDescription:A local business rule relating multiple elements has been violated.
CODE_INVALhttp://hl7.org/fhir/v3/ActCodecode is not validDescription:The specified code is not valid against the list of codes allowed for the element.
CODE_DEPREChttp://hl7.org/fhir/v3/ActCodecode has been deprecatedDescription:The specified code has been deprecated and should no longer be used. Select another code from the code system.
FORMAThttp://hl7.org/fhir/v3/ActCodeinvalid formatDescription:The element does not follow the formatting or type rules defined for the field.
ILLEGALhttp://hl7.org/fhir/v3/ActCodeillegalDescription:The request is missing elements or contains elements which cause it to not meet the legal standards for actioning.
LEN_RANGEhttp://hl7.org/fhir/v3/ActCodelength out of rangeDescription:The length of the data specified falls out of the range defined for the element.
LEN_LONGhttp://hl7.org/fhir/v3/ActCodelength is too longDescription:The length of the data specified is greater than the maximum length defined for the element.
LEN_SHORThttp://hl7.org/fhir/v3/ActCodelength is too shortDescription:The length of the data specified is less than the minimum length defined for the element.
MISSCONDhttp://hl7.org/fhir/v3/ActCodeconditional element missingDescription:The specified element must be specified with a non-null value under certain conditions. In this case, the conditions are true but the element is still missing or null.
MISSMANDhttp://hl7.org/fhir/v3/ActCodemandatory element missingDescription:The specified element is mandatory and was not included in the instance.
NODUPShttp://hl7.org/fhir/v3/ActCodeduplicate values are not permittedDescription:More than one element with the same value exists in the set. Duplicates not permission in this set in a set.
NOPERSISThttp://hl7.org/fhir/v3/ActCodeelement will not be persistedDescription: Element in submitted message will not persist in data storage based on detected issue.
REP_RANGEhttp://hl7.org/fhir/v3/ActCoderepetitions out of rangeDescription:The number of repeating elements falls outside the range of the allowed number of repetitions.
MAXOCCURShttp://hl7.org/fhir/v3/ActCoderepetitions above maximumDescription:The number of repeating elements is above the maximum number of repetitions allowed.
MINOCCURShttp://hl7.org/fhir/v3/ActCoderepetitions below minimumDescription:The number of repeating elements is below the minimum number of repetitions allowed.
_ActAdministrativeRuleDetectedIssueCodehttp://hl7.org/fhir/v3/ActCodeActAdministrativeRuleDetectedIssueCodeActAdministrativeRuleDetectedIssueCode
KEY206http://hl7.org/fhir/v3/ActCodenon-matching identificationDescription: Metadata associated with the identification (e.g. name or gender) does not match the identification being verified.
OBSOLETEhttp://hl7.org/fhir/v3/ActCodeobsolete record returnedDescription: One or more records in the query response have a status of 'obsolete'.
_ActSuppliedItemDetectedIssueCodehttp://hl7.org/fhir/v3/ActCodeActSuppliedItemDetectedIssueCodeIdentifies types of detected issues regarding the administration or supply of an item to a patient.
_AdministrationDetectedIssueCodehttp://hl7.org/fhir/v3/ActCodeAdministrationDetectedIssueCodeAdministration of the proposed therapy may be inappropriate or contraindicated as proposed
_AppropriatenessDetectedIssueCodehttp://hl7.org/fhir/v3/ActCodeAppropriatenessDetectedIssueCodeAppropriatenessDetectedIssueCode
_InteractionDetectedIssueCodehttp://hl7.org/fhir/v3/ActCodeInteractionDetectedIssueCodeInteractionDetectedIssueCode
FOODhttp://hl7.org/fhir/v3/ActCodeFood Interaction AlertProposed therapy may interact with certain foods
TPRODhttp://hl7.org/fhir/v3/ActCodeTherapeutic Product AlertProposed therapy may interact with an existing or recent therapeutic product
DRGhttp://hl7.org/fhir/v3/ActCodeDrug Interaction AlertProposed therapy may interact with an existing or recent drug therapy
NHPhttp://hl7.org/fhir/v3/ActCodeNatural Health Product AlertProposed therapy may interact with existing or recent natural health product therapy
NONRXhttp://hl7.org/fhir/v3/ActCodeNon-Prescription Interaction AlertProposed therapy may interact with a non-prescription drug (e.g. alcohol, tobacco, Aspirin)
PREVINEFhttp://hl7.org/fhir/v3/ActCodepreviously ineffectiveDefinition:The same or similar treatment has previously been attempted with the patient without achieving a positive effect.
DACThttp://hl7.org/fhir/v3/ActCodedrug action detected issueDescription:Proposed therapy may be contraindicated or ineffective based on an existing or recent drug therapy.
TIMEhttp://hl7.org/fhir/v3/ActCodetiming detected issueDescription:Proposed therapy may be inappropriate or ineffective based on the proposed start or end time.
ALRTENDLATEhttp://hl7.org/fhir/v3/ActCodeend too late alertDefinition:Proposed therapy may be inappropriate or ineffective because the end of administration is too close to another planned therapy.
ALRTSTRTLATEhttp://hl7.org/fhir/v3/ActCodestart too late alertDefinition:Proposed therapy may be inappropriate or ineffective because the start of administration is too late after the onset of the condition.
_TimingDetectedIssueCodehttp://hl7.org/fhir/v3/ActCodeTimingDetectedIssueCodeProposed therapy may be inappropriate or ineffective based on the proposed start or end time.
ENDLATEhttp://hl7.org/fhir/v3/ActCodeEnd Too Late AlertProposed therapy may be inappropriate or ineffective because the end of administration is too close to another planned therapy
STRTLATEhttp://hl7.org/fhir/v3/ActCodeStart Too Late AlertProposed therapy may be inappropriate or ineffective because the start of administration is too late after the onset of the condition
_SupplyDetectedIssueCodehttp://hl7.org/fhir/v3/ActCodeSupplyDetectedIssueCodeSupplying the product at this time may be inappropriate or indicate compliance issues with the associated therapy
ALLDONEhttp://hl7.org/fhir/v3/ActCodealready performedDefinition:The requested action has already been performed and so this request has no effect
FULFILhttp://hl7.org/fhir/v3/ActCodefulfillment alertDefinition:The therapy being performed is in some way out of alignment with the requested therapy.
NOTACTNhttp://hl7.org/fhir/v3/ActCodeno longer actionableDefinition:The status of the request being fulfilled has changed such that it is no longer actionable. This may be because the request has expired, has already been completely fulfilled or has been otherwise stopped or disabled. (Not used for 'suspended' orders.)
NOTEQUIVhttp://hl7.org/fhir/v3/ActCodenot equivalent alertDefinition:The therapy being performed is not sufficiently equivalent to the therapy which was requested.
NOTEQUIVGENhttp://hl7.org/fhir/v3/ActCodenot generically equivalent alertDefinition:The therapy being performed is not generically equivalent (having the identical biological action) to the therapy which was requested.
NOTEQUIVTHERhttp://hl7.org/fhir/v3/ActCodenot therapeutically equivalent alertDefinition:The therapy being performed is not therapeutically equivalent (having the same overall patient effect) to the therapy which was requested.
TIMINGhttp://hl7.org/fhir/v3/ActCodeevent timing incorrect alertDefinition:The therapy is being performed at a time which diverges from the time the therapy was requested
INTERVALhttp://hl7.org/fhir/v3/ActCodeoutside requested timeDefinition:The therapy action is being performed outside the bounds of the time period requested
MINFREQhttp://hl7.org/fhir/v3/ActCodetoo soon within frequency based on the usageDefinition:The therapy action is being performed too soon after the previous occurrence based on the requested frequency
HELDhttp://hl7.org/fhir/v3/ActCodeheld/suspended alertDefinition:There should be no actions taken in fulfillment of a request that has been held or suspended.
TOOLATEhttp://hl7.org/fhir/v3/ActCodeRefill Too Late AlertThe patient is receiving a subsequent fill significantly later than would be expected based on the amount previously supplied and the therapy dosage instructions
TOOSOONhttp://hl7.org/fhir/v3/ActCodeRefill Too Soon AlertThe patient is receiving a subsequent fill significantly earlier than would be expected based on the amount previously supplied and the therapy dosage instructions
HISTORIChttp://hl7.org/fhir/v3/ActCoderecord recorded as historicalDescription: While the record was accepted in the repository, there is a more recent version of a record of this type.
PATPREFhttp://hl7.org/fhir/v3/ActCodeviolates stated preferencesDefinition:The proposed therapy goes against preferences or consent constraints recorded in the patient's record.
PATPREFALThttp://hl7.org/fhir/v3/ActCodeviolates stated preferences, alternate availableDefinition:The proposed therapy goes against preferences or consent constraints recorded in the patient's record. An alternate therapy meeting those constraints is available.
KSUBJhttp://hl7.org/fhir/v3/ActCodeknowledge subjectCategorization of types of observation that capture the main clinical knowledge subject which may be a medication, a laboratory test, a disease.
KSUBThttp://hl7.org/fhir/v3/ActCodeknowledge subtopicCategorization of types of observation that capture a knowledge subtopic which might be treatment, etiology, or prognosis.
OINThttp://hl7.org/fhir/v3/ActCodeintoleranceHypersensitivity resulting in an adverse reaction upon exposure to an agent.
ALGhttp://hl7.org/fhir/v3/ActCodeAllergyHypersensitivity to an agent caused by an immunologic response to an initial exposure
DALGhttp://hl7.org/fhir/v3/ActCodeDrug AllergyAn allergy to a pharmaceutical product.
EALGhttp://hl7.org/fhir/v3/ActCodeEnvironmental AllergyAn allergy to a substance other than a drug or a food. E.g. Latex, pollen, etc.
FALGhttp://hl7.org/fhir/v3/ActCodeFood AllergyAn allergy to a substance generally consumed for nutritional purposes.
DINThttp://hl7.org/fhir/v3/ActCodeDrug IntoleranceHypersensitivity resulting in an adverse reaction upon exposure to a drug.
DNAINThttp://hl7.org/fhir/v3/ActCodeDrug Non-Allergy IntoleranceHypersensitivity to an agent caused by a mechanism other than an immunologic response to an initial exposure
EINThttp://hl7.org/fhir/v3/ActCodeEnvironmental IntoleranceHypersensitivity resulting in an adverse reaction upon exposure to environmental conditions.
ENAINThttp://hl7.org/fhir/v3/ActCodeEnvironmental Non-Allergy IntoleranceHypersensitivity to an agent caused by a mechanism other than an immunologic response to an initial exposure
FINThttp://hl7.org/fhir/v3/ActCodeFood IntoleranceHypersensitivity resulting in an adverse reaction upon exposure to food.
FNAINThttp://hl7.org/fhir/v3/ActCodeFood Non-Allergy IntoleranceHypersensitivity to an agent caused by a mechanism other than an immunologic response to an initial exposure
NAINThttp://hl7.org/fhir/v3/ActCodeNon-Allergy IntoleranceHypersensitivity to an agent caused by a mechanism other than an immunologic response to an initial exposure
SEVhttp://hl7.org/fhir/v3/ActCodeSeverity ObservationA subjective evaluation of the seriousness or intensity associated with another observation.
_FDALabelDatahttp://hl7.org/fhir/v3/ActCodeFDALabelDataFDA label data
FDACOATINGhttp://hl7.org/fhir/v3/ActCodecoatingFDA label coating
FDACOLORhttp://hl7.org/fhir/v3/ActCodecolorFDA label color
FDAIMPRINTCDhttp://hl7.org/fhir/v3/ActCodeimprint codeFDA label imprint code
FDALOGOhttp://hl7.org/fhir/v3/ActCodelogoFDA label logo
FDASCORINGhttp://hl7.org/fhir/v3/ActCodescoringFDA label scoring
FDASHAPEhttp://hl7.org/fhir/v3/ActCodeshapeFDA label shape
FDASIZEhttp://hl7.org/fhir/v3/ActCodesizeFDA label size
1-8 http://loinc.orgAcyclovir [Susceptibility]
10-9 http://loinc.orgAmdinocillin [Susceptibility] by Serum bactericidal titer
100-8 http://loinc.orgCefoperazone [Susceptibility] by Minimum inhibitory concentration (MIC)
1000-9 http://loinc.orgDBG Ab [Presence] in Serum or Plasma from Blood product unit
10000-8 http://loinc.orgR wave duration in lead AVR
10001-6 http://loinc.orgR wave duration in lead I
10002-4 http://loinc.orgR wave duration in lead II
10003-2 http://loinc.orgR wave duration in lead III
10004-0 http://loinc.orgR wave duration in lead V1
10005-7 http://loinc.orgR wave duration in lead V2
10006-5 http://loinc.orgR wave duration in lead V3
10007-3 http://loinc.orgR wave duration in lead V4
10008-1 http://loinc.orgR wave duration in lead V5
10009-9 http://loinc.orgR wave duration in lead V6
1001-7 http://loinc.orgDBG Ab [Presence] in Serum or Plasma from donor
10010-7 http://loinc.orgR' wave amplitude in lead AVF
10011-5 http://loinc.orgR' wave amplitude in lead AVL
10012-3 http://loinc.orgR' wave amplitude in lead AVR
10013-1 http://loinc.orgR' wave amplitude in lead I
10014-9 http://loinc.orgR' wave amplitude in lead II
10015-6 http://loinc.orgR' wave amplitude in lead III
10016-4 http://loinc.orgR' wave amplitude in lead V1
10017-2 http://loinc.orgR' wave amplitude in lead V2
10018-0 http://loinc.orgR' wave amplitude in lead V3
10019-8 http://loinc.orgR' wave amplitude in lead V4
1002-5 http://loinc.orgDBG Ab [Presence] in Serum or Plasma
10020-6 http://loinc.orgR' wave amplitude in lead V5
10021-4 http://loinc.orgR' wave amplitude in lead V6
10022-2 http://loinc.orgR' wave duration in lead AVF
10023-0 http://loinc.orgR' wave duration in lead AVL
10024-8 http://loinc.orgR' wave duration in lead AVR
10025-5 http://loinc.orgR' wave duration in lead I
10026-3 http://loinc.orgR' wave duration in lead II
10027-1 http://loinc.orgR' wave duration in lead III
10028-9 http://loinc.orgR' wave duration in lead V1
10029-7 http://loinc.orgR' wave duration in lead V2
1003-3 http://loinc.orgIndirect antiglobulin test.complement specific reagent [Presence] in Serum or Plasma
10030-5 http://loinc.orgR' wave duration in lead V3
10031-3 http://loinc.orgR' wave duration in lead V4
10032-1 http://loinc.orgR' wave duration in lead V5
10033-9 http://loinc.orgR' wave duration in lead V6
10034-7 http://loinc.orgS wave amplitude in lead AVF
10035-4 http://loinc.orgS wave amplitude in lead AVL
10036-2 http://loinc.orgS wave amplitude in lead AVR
10037-0 http://loinc.orgS wave amplitude in lead I
10038-8 http://loinc.orgS wave amplitude in lead II
10039-6 http://loinc.orgS wave amplitude in lead III
1004-1 http://loinc.orgDirect antiglobulin test.complement specific reagent [Presence] on Red Blood Cells
10040-4 http://loinc.orgS wave amplitude in lead V1
10041-2 http://loinc.orgS wave amplitude in lead V2
10042-0 http://loinc.orgS wave amplitude in lead V3
10043-8 http://loinc.orgS wave amplitude in lead V4
10044-6 http://loinc.orgS wave amplitude in lead V5
10045-3 http://loinc.orgS wave amplitude in lead V6
10046-1 http://loinc.orgS wave duration in lead AVF
10047-9 http://loinc.orgS wave duration in lead AVL
10048-7 http://loinc.orgS wave duration in lead AVR
10049-5 http://loinc.orgS wave duration in lead I
1005-8 http://loinc.orgIndirect antiglobulin test.IgG specific reagent [Presence] in Serum or Plasma
10050-3 http://loinc.orgS wave duration in lead II
10051-1 http://loinc.orgS wave duration in lead III
10052-9 http://loinc.orgS wave duration in lead V1
10053-7 http://loinc.orgS wave duration in lead V2
10054-5 http://loinc.orgS wave duration in lead V3
10055-2 http://loinc.orgS wave duration in lead V4
10056-0 http://loinc.orgS wave duration in lead V5
10057-8 http://loinc.orgS wave duration in lead V6
10058-6 http://loinc.orgS' wave amplitude in lead AVF
10059-4 http://loinc.orgS' wave amplitude in lead AVL
1006-6 http://loinc.orgDirect antiglobulin test.IgG specific reagent [Interpretation] on Red Blood Cells
10060-2 http://loinc.orgS' wave amplitude in lead AVR
10061-0 http://loinc.orgS' wave amplitude in lead I
10062-8 http://loinc.orgS' wave amplitude in lead II
10063-6 http://loinc.orgS' wave amplitude in lead III
10064-4 http://loinc.orgS' wave amplitude in lead V1
10065-1 http://loinc.orgS' wave amplitude in lead V2
10066-9 http://loinc.orgS' wave amplitude in lead V3
10067-7 http://loinc.orgS' wave amplitude in lead V4
10068-5 http://loinc.orgS' wave amplitude in lead V5
10069-3 http://loinc.orgS' wave amplitude in lead V6
1007-4 http://loinc.orgDirect antiglobulin test.poly specific reagent [Presence] on Red Blood Cells
10070-1 http://loinc.orgS' wave duration in lead AVF
10071-9 http://loinc.orgS' wave duration in lead AVL
10072-7 http://loinc.orgS' wave duration in lead AVR
10073-5 http://loinc.orgS' wave duration in lead I
10074-3 http://loinc.orgS' wave duration in lead II
10075-0 http://loinc.orgS' wave duration in lead III
10076-8 http://loinc.orgS' wave duration in lead V1
10077-6 http://loinc.orgS' wave duration in lead V2
10078-4 http://loinc.orgS' wave duration in lead V3
10079-2 http://loinc.orgS' wave duration in lead V4
1008-2 http://loinc.orgIndirect antiglobulin test.poly specific reagent [Presence] in Serum or Plasma
10080-0 http://loinc.orgS' wave duration in lead V5
10081-8 http://loinc.orgS' wave duration in lead V6
10082-6 http://loinc.orgST initial amplitude 6 ms in lead AVF
10083-4 http://loinc.orgST initial amplitude 6 ms in lead AVL
10084-2 http://loinc.orgST initial amplitude 6 ms in lead AVR
10085-9 http://loinc.orgST initial amplitude 6 ms in lead I
10086-7 http://loinc.orgST initial amplitude 6 ms in lead II
10087-5 http://loinc.orgST initial amplitude 6 ms in lead III
10088-3 http://loinc.orgST initial amplitude 6 ms in lead V1
10089-1 http://loinc.orgST initial amplitude 6 ms in lead V2
1009-0 http://loinc.orgDeprecated Direct antiglobulin test.poly specific reagent [Presence] on Red Blood Cells
10090-9 http://loinc.orgST initial amplitude 6 ms in lead V3
10091-7 http://loinc.orgST initial amplitude 6 ms in lead V4
10092-5 http://loinc.orgST initial amplitude 6 ms in lead V5
10093-3 http://loinc.orgST initial amplitude 6 ms in lead V6
10094-1 http://loinc.orgST slope in lead AVF
10095-8 http://loinc.orgST slope in lead AVL
10096-6 http://loinc.orgST slope in lead AVR
10097-4 http://loinc.orgST slope in lead I
10098-2 http://loinc.orgST slope in lead II
10099-0 http://loinc.orgST slope in lead III
101-6 http://loinc.orgCefoperazone [Susceptibility] by Disk diffusion (KB)
1010-8 http://loinc.orgEw Ab [Presence] in Serum or Plasma from Blood product unit
10100-6 http://loinc.orgST slope in lead V1
10101-4 http://loinc.orgST slope in lead V2
10102-2 http://loinc.orgST slope in lead V3
10103-0 http://loinc.orgST slope in lead V4
10104-8 http://loinc.orgST slope in lead V5
10105-5 http://loinc.orgST slope in lead V6
10106-3 http://loinc.orgST wave end displacement in lead AVF
10107-1 http://loinc.orgST wave end displacement in lead AVL
10108-9 http://loinc.orgST wave end displacement in lead AVR
10109-7 http://loinc.orgST wave end displacement in lead I
1011-6 http://loinc.orgEw Ab [Presence] in Serum or Plasma from donor
10110-5 http://loinc.orgST wave end displacement in lead II
10111-3 http://loinc.orgST wave end displacement in lead III
10112-1 http://loinc.orgST wave end displacement in lead V1
10113-9 http://loinc.orgST wave end displacement in lead V2
10114-7 http://loinc.orgST wave end displacement in lead V3
10115-4 http://loinc.orgST wave end displacement in lead V4
10116-2 http://loinc.orgST wave end displacement in lead V5
10117-0 http://loinc.orgST wave end displacement in lead V6
10118-8 http://loinc.orgST wave mid displacement in lead AVF
10119-6 http://loinc.orgST wave mid displacement in lead AVL
1012-4 http://loinc.orgEw Ab [Presence] in Serum or Plasma
10120-4 http://loinc.orgST wave mid displacement in lead AVR
10121-2 http://loinc.orgST wave mid displacement in lead I
10122-0 http://loinc.orgST wave mid displacement in lead II
10123-8 http://loinc.orgST wave mid displacement in lead III
10124-6 http://loinc.orgST wave mid displacement in lead V1
10125-3 http://loinc.orgST wave mid displacement in lead V2
10126-1 http://loinc.orgST wave mid displacement in lead V3
10127-9 http://loinc.orgST wave mid displacement in lead V4
10128-7 http://loinc.orgST wave mid displacement in lead V5
10129-5 http://loinc.orgST wave mid displacement in lead V6
1013-2 http://loinc.orgEw Ag [Presence] on Red Blood Cells from Blood product unit
10130-3 http://loinc.orgT' wave amplitude in lead AVF
10131-1 http://loinc.orgT' wave amplitude in lead AVL
10132-9 http://loinc.orgT' wave amplitude in lead AVR
10133-7 http://loinc.orgT' wave amplitude in lead I
10134-5 http://loinc.orgT' wave amplitude in lead II
10135-2 http://loinc.orgT' wave amplitude in lead III
10136-0 http://loinc.orgT' wave amplitude in lead V1
10137-8 http://loinc.orgT' wave amplitude in lead V2
10138-6 http://loinc.orgT' wave amplitude in lead V3
10139-4 http://loinc.orgT' wave amplitude in lead V4
1014-0 http://loinc.orgEw Ag [Presence] on Red Blood Cells from donor
10140-2 http://loinc.orgT' wave amplitude in lead V5
10141-0 http://loinc.orgT' wave amplitude in lead V6
10142-8 http://loinc.orgT wave amplitude in lead AVF
10143-6 http://loinc.orgT wave amplitude in lead AVL
10144-4 http://loinc.orgT wave amplitude in lead AVR
10145-1 http://loinc.orgT wave amplitude in lead I
10146-9 http://loinc.orgT wave amplitude in lead II
10147-7 http://loinc.orgT wave amplitude in lead III
10148-5 http://loinc.orgT wave amplitude in lead V1
10149-3 http://loinc.orgT wave amplitude in lead V2
1015-7 http://loinc.orgEw Ag [Presence] on Red Blood Cells
10150-1 http://loinc.orgT wave amplitude in lead V3
10151-9 http://loinc.orgT wave amplitude in lead V4
10152-7 http://loinc.orgT wave amplitude in lead V5
10153-5 http://loinc.orgT wave amplitude in lead V6
10154-3 http://loinc.orgChief complaint Narrative - Reported
10155-0 http://loinc.orgHistory of allergies, reported
10156-8 http://loinc.orgHistory of Childhood diseases Narrative
10157-6 http://loinc.orgHistory of family member diseases Narrative
10158-4 http://loinc.orgHistory of Functional status Narrative
10159-2 http://loinc.orgHistory of Industrial exposure Narrative
1016-5 http://loinc.orgE Ab [Presence] in Serum or Plasma from Blood product unit
10160-0 http://loinc.orgHistory of Medication use Narrative
10161-8 http://loinc.orgHistory of Occupational exposure Narrative
10162-6 http://loinc.orgHistory of pregnancies Narrative
10163-4 http://loinc.orgHistory of pregnancies
10164-2 http://loinc.orgHistory of Present illness Narrative
10165-9 http://loinc.orgDeprecated History of psychiatric symptoms and diseases Narrative
10166-7 http://loinc.orgHistory of Social function Narrative
10167-5 http://loinc.orgHistory of Surgical procedures Narrative
10168-3 http://loinc.orgHistory of Cardiovascular system disorders Narrative
10169-1 http://loinc.orgHistory of Ear disorders Narrative
1017-3 http://loinc.orgE Ab [Presence] in Serum or Plasma from donor
10170-9 http://loinc.orgHistory of Endocrine system disorders Narrative
10171-7 http://loinc.orgHistory of Eyes disorders Narrative
10172-5 http://loinc.orgHistory of Hematologic system disorders Narrative
10173-3 http://loinc.orgHistory of Musculoskeletal system disorders Narrative
10174-1 http://loinc.orgHistory of Nose disorders Narrative
10175-8 http://loinc.orgHistory of Oral cavity disorders Narrative
10176-6 http://loinc.orgHistory of Reproductive system disorders Narrative
10177-4 http://loinc.orgHistory of Respiratory system disorders Narrative
10178-2 http://loinc.orgHistory of Skin disorders Narrative
10179-0 http://loinc.orgHistory of Throat and Neck disorders Narrative
1018-1 http://loinc.orgE Ab [Presence] in Serum or Plasma
10180-8 http://loinc.orgHistory of Throat and Neck disorders
10181-6 http://loinc.orgHistory of Urinary tract disorders Narrative
10182-4 http://loinc.orgHistory of Travel Narrative
10183-2 http://loinc.orgHospital discharge medications Narrative
10184-0 http://loinc.orgHospital discharge physical findings Narrative
10185-7 http://loinc.orgHospital discharge procedures Narrative
10186-5 http://loinc.orgIdentifying information Narrative Observed
10187-3 http://loinc.orgReview of systems Narrative - Reported
10188-1 http://loinc.orgReview of systems overview Narrative - Reported
10189-9 http://loinc.orgReview of systems overview - Reported
1019-9 http://loinc.orgE Ag [Presence] on Red Blood Cells from Blood product unit
10190-7 http://loinc.orgMental status Narrative
10191-5 http://loinc.orgPhysical findings of Abdomen Narrative
10192-3 http://loinc.orgPhysical findings of Back Narrative
10193-1 http://loinc.orgPhysical findings of Breasts Narrative
10194-9 http://loinc.orgPhysical findings of Neurologic deep tendon reflexes Narrative
10195-6 http://loinc.orgPhysical findings of Ear Narrative
10196-4 http://loinc.orgPhysical findings of Extremities Narrative
10197-2 http://loinc.orgPhysical findings of Eye Narrative
10198-0 http://loinc.orgPhysical findings of Genitourinary tract Narrative
10199-8 http://loinc.orgPhysical findings of Head Narrative
102-4 http://loinc.orgCefoperazone [Susceptibility] by Serum bactericidal titer
1020-7 http://loinc.orgE Ag [Presence] on Red Blood Cells from donor
10200-4 http://loinc.orgPhysical findings of Heart Narrative
10201-2 http://loinc.orgPhysical findings of Mouth and Throat and Teeth Narrative
10202-0 http://loinc.orgPhysical findings of Nervous system Narrative
10203-8 http://loinc.orgPhysical findings of Nose Narrative
10204-6 http://loinc.orgPhysical findings of Pelvis Narrative
10205-3 http://loinc.orgPhysical findings of Rectum Narrative
10206-1 http://loinc.orgPhysical findings of Skin Narrative
10207-9 http://loinc.orgPhysical findings of Thorax and Lungs Narrative
10208-7 http://loinc.orgPhysical findings of Vessels Narrative
10209-5 http://loinc.orgPhysical findings of Neurologic balance and Coordination Narrative
1021-5 http://loinc.orgE Ag [Presence] on Red Blood Cells
10210-3 http://loinc.orgPhysical findings of General status Narrative
10211-1 http://loinc.orgPhysical findings of Sense of touch Narrative
10212-9 http://loinc.orgPhysical findings of Strength Narrative
10213-7 http://loinc.orgSurgical operation note anesthesia Narrative
10214-5 http://loinc.orgSurgical operation note anesthesia duration
10215-2 http://loinc.orgSurgical operation note findings Narrative
10216-0 http://loinc.orgSurgical operation note fluids Narrative
10217-8 http://loinc.orgSurgical operation note indications [Interpretation] Narrative
10218-6 http://loinc.orgSurgical operation note postoperative diagnosis Narrative
10219-4 http://loinc.orgSurgical operation note preoperative diagnosis Narrative
1022-3 http://loinc.orgFy sup(a) Ab [Presence] in Serum or Plasma from Blood product unit
10220-2 http://loinc.orgSurgical operation note prep time duration
10221-0 http://loinc.orgSurgical operation note specimens taken Narrative
10222-8 http://loinc.orgSurgical operation note surgical complications [Interpretation] Narrative
10223-6 http://loinc.orgSurgical operation note surgical procedure Narrative
10224-4 http://loinc.orgHemodynamic method special circumstances
10225-1 http://loinc.orgCardiac measurement device Institution inventory number
10226-9 http://loinc.orgOxygen content in Intravascular space
10227-7 http://loinc.orgCardiac measurement device Vendor model number
10228-5 http://loinc.orgCardiac measurement device Vendor serial number
10229-3 http://loinc.orgHemodynamic method Type of
1023-1 http://loinc.orgFy sup(a) Ab [Presence] in Serum or Plasma from donor
10230-1 http://loinc.orgLeft ventricular Ejection fraction
10231-9 http://loinc.orgRight ventricular Ejection fraction
10232-7 http://loinc.orgOxygen content in Aorta root
10233-5 http://loinc.orgOxygen content in Left atrium
10234-3 http://loinc.orgOxygen content in Right atrium
10235-0 http://loinc.orgOxygen content in High right atrium
10236-8 http://loinc.orgOxygen content in Low right atrium
10237-6 http://loinc.orgOxygen content in Mid right atrium
10238-4 http://loinc.orgOxygen content in Left ventricle
10239-2 http://loinc.orgOxygen content in Right ventricular outflow tract
1024-9 http://loinc.orgFy sup(a) Ab [Presence] in Serum or Plasma
10240-0 http://loinc.orgOxygen content in Right ventricle
10241-8 http://loinc.orgOxygen content in Coronary sinus
10242-6 http://loinc.orgOxygen content in Ductus arteriosus
10243-4 http://loinc.orgOxygen content in Inferior vena cava
10244-2 http://loinc.orgOxygen content in Left pulmonary artery
10245-9 http://loinc.orgOxygen content in Main pulmonary artery
10246-7 http://loinc.orgOxygen content in Right pulmonary artery
10247-5 http://loinc.orgOxygen content in Pulmonary wedge
10248-3 http://loinc.orgOxygen content in Superior vena cava
10249-1 http://loinc.orgHeart rate device Institution inventory number
1025-6 http://loinc.orgFy sup(a) Ag [Presence] on Red Blood Cells from Blood product unit
10250-9 http://loinc.orgHeart rate device Vendor model number
10251-7 http://loinc.orgHeart rate device Vendor serial number
10252-5 http://loinc.orgBiliary drain site
10253-3 http://loinc.orgType of Biliary drain
10254-1 http://loinc.orgType of Peritoneal drain
10255-8 http://loinc.orgType of Subarachnoid drain
10256-6 http://loinc.orgBiliary drain Institution inventory number
10257-4 http://loinc.orgChest tube Institution inventory number
10258-2 http://loinc.orgEnteral tube Institution inventory number
10259-0 http://loinc.orgGastrostomy tube Institution inventory number
1026-4 http://loinc.orgFy sup(a) Ag [Presence] on Red Blood Cells from donor
10260-8 http://loinc.orgGI tube Institution inventory number
10261-6 http://loinc.orgIntravascular tube Institution inventory number
10262-4 http://loinc.orgIO tube Institution inventory number
10263-2 http://loinc.orgNasogastric tube Institution inventory number
10264-0 http://loinc.orgOral tube Institution inventory number
10265-7 http://loinc.orgPeritoneal drain Institution inventory number
10266-5 http://loinc.orgPeritoneal tube Institution inventory number
10267-3 http://loinc.orgRate control device Institution inventory number
10268-1 http://loinc.orgStool collection device Institution inventory number
10269-9 http://loinc.orgSubarachnoid drain Institution inventory number
1027-2 http://loinc.orgFy sup(a) Ag [Presence] on Red Blood Cells
10270-7 http://loinc.orgSynovial drain Institution inventory number
10271-5 http://loinc.orgTube or drain Institution inventory number
10272-3 http://loinc.orgUpper GI tube Institution inventory number
10273-1 http://loinc.orgBladder irrigation tube Institution inventory number
10274-9 http://loinc.orgUrine tube Institution inventory number
10275-6 http://loinc.orgWound drain device Institution inventory number
10276-4 http://loinc.orgPeritoneal drain site
10277-2 http://loinc.orgStool collection site
10278-0 http://loinc.orgSubarachnoid drain site
10279-8 http://loinc.orgBiliary drain Vendor model number
1028-0 http://loinc.orgFy sup(b) Ab [Presence] in Serum or Plasma from Blood product unit
10280-6 http://loinc.orgChest tube Vendor model number
10281-4 http://loinc.orgEnteral tube Vendor model number
10282-2 http://loinc.orgGastrostomy tube Vendor model number
10283-0 http://loinc.orgGI tube Vendor model number
10284-8 http://loinc.orgIntravascular tube Vendor model number
10285-5 http://loinc.orgIO tube Vendor model number
10286-3 http://loinc.orgNasogastric tube Vendor model number
10287-1 http://loinc.orgOral tube Vendor model number
10288-9 http://loinc.orgPeritoneal drain Vendor model number
10289-7 http://loinc.orgPeritoneal tube Vendor model number
1029-8 http://loinc.orgFy sup(b) Ab [Presence] in Serum or Plasma from donor
10290-5 http://loinc.orgRate control device Vendor model number
10291-3 http://loinc.orgStool collection device Vendor model number
10292-1 http://loinc.orgSubarachnoid drain Vendor model number
10293-9 http://loinc.orgSynovial drain Vendor model number
10294-7 http://loinc.orgTube or drain Vendor model number
10295-4 http://loinc.orgUpper GI tube Vendor model number
10296-2 http://loinc.orgBladder irrigation tube Vendor model number
10297-0 http://loinc.orgUrine tube Vendor model number
10298-8 http://loinc.orgWound drain device Vendor model number
10299-6 http://loinc.orgBiliary drain Vendor serial number
103-2 http://loinc.orgCeforanide [Susceptibility] by Minimum lethal concentration (MLC)
1030-6 http://loinc.orgFy sup(b) Ab [Presence] in Serum or Plasma
10300-2 http://loinc.orgChest tube Vendor serial number
10301-0 http://loinc.orgEnteral tube Vendor serial number
10302-8 http://loinc.orgGastrostomy tube Vendor serial number
10303-6 http://loinc.orgGI tube Vendor serial number
10304-4 http://loinc.orgIntravascular tube Vendor serial number
10305-1 http://loinc.orgIO tube Vendor serial number
10306-9 http://loinc.orgNasogastric tube Vendor serial number
10307-7 http://loinc.orgOral tube Vendor serial number
10308-5 http://loinc.orgPeritoneal drain Vendor serial number
10309-3 http://loinc.orgPeritoneal tube Vendor serial number
1031-4 http://loinc.orgFy sup(b) Ag [Presence] on Red Blood Cells from Blood product unit
10310-1 http://loinc.orgRate control device Vendor serial number
10311-9 http://loinc.orgStool collection device Vendor serial number
10312-7 http://loinc.orgSubarachnoid drain Vendor serial number
10313-5 http://loinc.orgSynovial drain Vendor serial number
10314-3 http://loinc.orgTube or drain Vendor serial number
10315-0 http://loinc.orgUpper GI tube Vendor serial number
10316-8 http://loinc.orgBladder irrigation tube Vendor serial number
10317-6 http://loinc.orgUrine tube Vendor serial number
10318-4 http://loinc.orgWound drain device Vendor serial number
10319-2 http://loinc.orgEnema device Institution inventory number
1032-2 http://loinc.orgFy sup(b) Ag [Presence] on Red Blood Cells from donor
10320-0 http://loinc.orgEnema device Vendor model number
10321-8 http://loinc.orgEnema device Vendor serial number
10322-6 http://loinc.orgPotassium intake 24 hour
10323-4 http://loinc.orgWound drain fluid [Appearance] Lower GI tract
10324-2 http://loinc.orgBreath rate device Institution inventory number
10325-9 http://loinc.orgBreath rate device Vendor model number
10326-7 http://loinc.orgBreath rate device Vendor serial number
10327-5 http://loinc.orgEosinophils/100 leukocytes in Sputum by Manual count
10328-3 http://loinc.orgLymphocytes/100 leukocytes in Cerebral spinal fluid by Manual count
10329-1 http://loinc.orgMonocytes/100 leukocytes in Cerebral spinal fluid by Manual count
1033-0 http://loinc.orgFy sup(b) Ag [Presence] on Red Blood Cells
10330-9 http://loinc.orgMonocytes/100 leukocytes in Body fluid by Manual count
10331-7 http://loinc.orgRh [Type] in Blood
10332-5 http://loinc.orgCortisol [Mass/volume] in Serum or Plasma --pre 250 ug corticotropin IM
10333-3 http://loinc.orgAppearance of Cerebral spinal fluid
10334-1 http://loinc.orgCancer Ag 125 [Units/volume] in Serum or Plasma
10335-8 http://loinc.orgColor of Cerebral spinal fluid
10336-6 http://loinc.orgGonadotropin peptide [Mass/volume] in Urine
10337-4 http://loinc.orgProcollagen type I [Mass/volume] in Serum
10338-2 http://loinc.orgBarbiturates [Mass/volume] in Serum or Plasma
10339-0 http://loinc.orgFluoxetine+Norfluoxetine [Mass/volume] in Serum or Plasma
1034-8 http://loinc.orgFetal cell screen [Interpretation] in Blood
10340-8 http://loinc.orgMolindone [Mass/volume] in Serum or Plasma
10341-6 http://loinc.orgNorpropoxyphene [Mass/volume] in Serum or Plasma
10342-4 http://loinc.orgSulfamethoxazole [Mass/volume] in Serum or Plasma
10343-2 http://loinc.orgTemazepam [Mass/volume] in Serum or Plasma
10344-0 http://loinc.orgTranylcypromine [Mass/volume] in Serum or Plasma
10345-7 http://loinc.orgTrihexyphenidyl [Mass/volume] in Urine
10346-5 http://loinc.orgHemoglobin A [Units/volume] in Blood by Electrophoresis
10347-3 http://loinc.orgBabesia microti identified in Blood by Light microscopy
10348-1 http://loinc.orgBordetella parapertussis Ab [Presence] in Serum
10349-9 http://loinc.orgBrucella sp Ab [Units/volume] in Serum
1035-5 http://loinc.orgFresh frozen plasma given [Volume]
10350-7 http://loinc.orgHerpes simplex virus IgM Ab [Titer] in Serum by Immunoassay
10351-5 http://loinc.orgHIV 1 RNA [Units/volume] (viral load) in Serum or Plasma by Probe with amplification
10352-3 http://loinc.orgBacteria identified in Genital specimen by Aerobe culture
10353-1 http://loinc.orgBacteria identified in Nose by Aerobe culture
10354-9 http://loinc.orgBacteria identified in Urethra by Culture
10355-6 http://loinc.orgMicroscopic observation [Identifier] in Bone marrow by Wright Giemsa stain
10356-4 http://loinc.orgDeprecated Microscopic observation [Identifier] in Stool by Trichrome stain
10357-2 http://loinc.orgMicroscopic observation [Identifier] in Wound by Gram stain
10358-0 http://loinc.orgTeichoate Ab [Titer] in Serum by Immune diffusion (ID)
10359-8 http://loinc.orgAsialoganglioside GM1 IgM Ab [Titer] in Serum
1036-3 http://loinc.orgG Ab [Presence] in Serum or Plasma from Blood product unit
10360-6 http://loinc.orgDNA single strand IgG Ab [Units/volume] in Serum
10361-4 http://loinc.orgDNA single strand IgM Ab [Units/volume] in Serum
10362-2 http://loinc.orgEndomysium IgA Ab [Presence] in Serum
10363-0 http://loinc.orgBarbiturates [Presence] in Unspecified specimen
10364-8 http://loinc.orgCotinine [Mass/mass] in Hair
10365-5 http://loinc.orgCotinine [Mass/volume] in Serum or Plasma
10366-3 http://loinc.orgCotinine [Mass/volume] in Urine
10367-1 http://loinc.orgEthanol [Mass/volume] in Gastric fluid
10368-9 http://loinc.orgLead [Mass/volume] in Capillary blood
10369-7 http://loinc.orgOpiates [Mass/mass] in Hair
1037-1 http://loinc.orgG Ab [Presence] in Serum or Plasma from donor
10370-5 http://loinc.orgPhencyclidine [Mass/mass] in Hair
10371-3 http://loinc.orgBite cells [Presence] in Blood by Light microscopy
10372-1 http://loinc.orgBlister cells [Presence] in Blood by Light microscopy
10373-9 http://loinc.orgFragments [Presence] in Blood by Light microscopy
10374-7 http://loinc.orgHelmet cells [Presence] in Blood by Light microscopy
10375-4 http://loinc.orgIrregularly contracted cells [Presence] in Blood by Light microscopy
10376-2 http://loinc.orgOval macrocytes [Presence] in Blood by Light microscopy
10377-0 http://loinc.orgPencil cells [Presence] in Blood by Light microscopy
10378-8 http://loinc.orgPolychromasia [Presence] in Blood by Light microscopy
10379-6 http://loinc.orgErythrocytes.dual population [Presence] in Blood by Light microscopy
1038-9 http://loinc.orgG Ab [Presence] in Serum or Plasma
10380-4 http://loinc.orgStomatocytes [Presence] in Blood by Light microscopy
10381-2 http://loinc.orgTarget cells [Presence] in Blood by Light microscopy
10382-0 http://loinc.orgA,B variant NOS Ag [Presence] on Red Blood Cells from Blood product unit
10383-8 http://loinc.orgA,B variant NOS Ag [Presence] on Red Blood Cells from donor
10384-6 http://loinc.orgA,B variant NOS Ag [Presence] on Red Blood Cells
10385-3 http://loinc.orgAlbumin concentration given
10386-1 http://loinc.orgAlbumin given [Volume]
10387-9 http://loinc.orgAutologous erythrocytes given [Volume]
10388-7 http://loinc.orgAutologous whole blood given [Volume]
10389-5 http://loinc.orgBlood product.other [Type]
1039-7 http://loinc.orgG Ag [Presence] on Red Blood Cells from Blood product unit
10390-3 http://loinc.orgBlood product special preparation [Type]
10391-1 http://loinc.orgCytomegalovirus immune globulin given [Volume]
10392-9 http://loinc.orgCryoprecipitate given [Volume]
10393-7 http://loinc.orgFactor IX given [Type]
10394-5 http://loinc.orgFactor IX given [Volume]
10395-2 http://loinc.orgFactor VIII given [Type]
10396-0 http://loinc.orgFactor VIII given [Volume]
10397-8 http://loinc.orgHepatitis B immune globulin given [Volume]
10398-6 http://loinc.orgI Ag [Presence] on Red Blood Cells from Blood product unit
10399-4 http://loinc.orgI Ag [Presence] on Red Blood Cells from donor
104-0 http://loinc.orgCeforanide [Susceptibility] by Minimum inhibitory concentration (MIC)
1040-5 http://loinc.orgG Ag [Presence] on Red Blood Cells from donor
10400-0 http://loinc.orgI Ag [Presence] on Red Blood Cells
10401-8 http://loinc.orgImmune serum globulin given [Type]
10402-6 http://loinc.orgImmune serum globulin given [Volume]
10403-4 http://loinc.orgInject immune serum globulin [Volume]
10404-2 http://loinc.orgInject Rh immune globulin [Volume]
10405-9 http://loinc.orgInject varicella zoster virus immune globulin [Volume]
10406-7 http://loinc.orglittle i Ag [Presence] on Red Blood Cells from Blood product unit
10407-5 http://loinc.orglittle i Ag [Presence] on Red Blood Cells from donor
10408-3 http://loinc.orglittle i Ag [Presence] on Red Blood Cells
10409-1 http://loinc.orgPentaspan given [Volume]
1041-3 http://loinc.orgG Ag [Presence] on Red Blood Cells
10410-9 http://loinc.orgPlasma given [Type]
10411-7 http://loinc.orgPlasma given [Volume]
10412-5 http://loinc.orgPlatelets given [Type]
10413-3 http://loinc.orgRh immune globulin given [Volume]
10414-1 http://loinc.orgTransfuse albumin [Volume]
10415-8 http://loinc.orgTransfuse blood exchange transfusion [Volume]
10416-6 http://loinc.orgTransfuse blood product other [Volume]
10417-4 http://loinc.orgTransfuse cryoprecipitate [Volume]
10418-2 http://loinc.orgTransfuse factor IX [Volume]
10419-0 http://loinc.orgTransfuse factor VIII [Volume]
1042-1 http://loinc.orgH Ab [Presence] in Serum or Plasma from Blood product unit
10420-8 http://loinc.orgTransfuse immune serum globulin [Volume]
10421-6 http://loinc.orgTransfuse Pentaspan [Volume]
10422-4 http://loinc.orgTransfuse plasma [Volume]
10423-2 http://loinc.orgTransfuse platelets [Volume]
10424-0 http://loinc.orgTransfuse erythrocytes [Volume]
10425-7 http://loinc.orgTransfuse Rh immune globulin [Volume]
10426-5 http://loinc.orgTransfuse whole blood [Volume]
10427-3 http://loinc.orgTransfuse whole blood autologous [Volume]
10428-1 http://loinc.orgVaricella zoster virus immune globulin given [Volume]
10429-9 http://loinc.orgAE 1 Ag [Presence] in Tissue by Immune stain
1043-9 http://loinc.orgH Ab [Presence] in Serum or Plasma from donor
10430-7 http://loinc.orgAE 3 Ag [Presence] in Tissue by Immune stain
10431-5 http://loinc.orgB-cell Ag [Presence] in Tissue by Immune stain
10432-3 http://loinc.orgCD30 Ag [Presence] in Tissue by Immune stain
10433-1 http://loinc.orgBR-2 Ag [Presence] in Tissue by Immune stain
10434-9 http://loinc.orgComplement C3 Ag [Presence] in Tissue by Immune stain
10435-6 http://loinc.orgC5B-9 Ag [Presence] in Tissue by Immune stain
10436-4 http://loinc.orgCD15 Ag [Presence] in Tissue by Immune stain
10437-2 http://loinc.orgCD16 Ag [Presence] in Tissue by Immune stain
10438-0 http://loinc.orgCD20 Ag [Presence] in Tissue by Immune stain
10439-8 http://loinc.orgCD3 Ag [Presence] in Tissue by Immune stain
1044-7 http://loinc.orgH Ab [Presence] in Serum
10440-6 http://loinc.orgDeprecated CD30 Ag [Presence] in Tissue by Immune stain
10441-4 http://loinc.orgCD34 Ag [Presence] in Tissue by Immune stain
10442-2 http://loinc.orgCD56 Ag [Presence] in Tissue by Immune stain
10443-0 http://loinc.orgCD43 T-cell monocyte+myeloid cell Ag [Presence] in Tissue by Immune stain
10444-8 http://loinc.orgCD57 Ag [Presence] in Tissue by Immune stain
10445-5 http://loinc.orgCD11c Ag [Presence] in Tissue by Immune stain
10446-3 http://loinc.orgLeukocyte common Ag [Presence] in Tissue by Immune stain
10447-1 http://loinc.orgM-5 Ag [Presence] in Tissue by Immune stain
10448-9 http://loinc.orgT-cell Ag [Presence] in Tissue by Immune stain
10449-7 http://loinc.orgGlucose [Mass/volume] in Serum or Plasma --1 hour post meal
1045-4 http://loinc.orgH NOS Ab [Presence] in Serum or Plasma from Blood product unit
10450-5 http://loinc.orgGlucose [Mass/volume] in Serum or Plasma --10 hours fasting
10451-3 http://loinc.orgProinsulin [Moles/volume] in Serum or Plasma --12 hours fasting
10452-1 http://loinc.orgXylose [Mass/volume] in Serum or Plasma --1 hour post 25 g xylose PO
10453-9 http://loinc.orgXylose [Mass/volume] in Serum or Plasma --1 hour post dose xylose PO
10454-7 http://loinc.orgXylose [Mass/volume] in Serum or Plasma --2 hours post 25 g xylose PO
10455-4 http://loinc.orgXylose [Mass/volume] in Serum or Plasma --30 minutes post 25 g xylose PO
10456-2 http://loinc.orgXylose [Mass/volume] in Serum or Plasma --6 hours fasting
10457-0 http://loinc.orgActin Ag [Presence] in Tissue by Immune stain
10458-8 http://loinc.orgAlkaline phosphatase.placental Ag [Presence] in Tissue by Immune stain
10459-6 http://loinc.orgAlpha-1-Fetoprotein Ag [Presence] in Tissue by Immune stain
1046-2 http://loinc.orgH NOS Ab [Presence] in Serum or Plasma from donor
10460-4 http://loinc.orgLactalbumin alpha Ag [Presence] in Tissue by Immune stain
10461-2 http://loinc.orgAlpha-1-Antichymotrypsin Ag [Presence] in Tissue by Immune stain
10462-0 http://loinc.orgAlpha 1 antitrypsin Ag [Presence] in Tissue by Immune stain
10463-8 http://loinc.orgAmyloid A component Ag [Presence] in Tissue by Immune stain
10464-6 http://loinc.orgAmyloid P component Ag [Presence] in Tissue by Immune stain
10465-3 http://loinc.orgAmyloid.prealbumin Ag [Presence] in Tissue by Immune stain
10466-1 http://loinc.orgAnion gap 3 in Serum or Plasma
10467-9 http://loinc.orgBeta-2-Microglobulin amyloid Ag [Presence] in Tissue by Immune stain
10468-7 http://loinc.orgCalcitonin Ag [Presence] in Tissue by Immune stain
10469-5 http://loinc.orgCarcinoembryonic Ag [Presence] in Tissue by Immune stain
1047-0 http://loinc.orgH NOS Ab [Presence] in Serum or Plasma
10470-3 http://loinc.orgChoriogonadotropin Ag [Presence] in Tissue by Immune stain
10471-1 http://loinc.orgChromogranin A Ag [Presence] in Tissue by Immune stain
10472-9 http://loinc.orgChromogranin Ag [Presence] in Tissue by Immune stain
10473-7 http://loinc.orgChymotrypsin Ag [Presence] in Tissue by Immune stain
10474-5 http://loinc.orgCollagen type 4 Ag [Presence] in Tissue by Immune stain
10475-2 http://loinc.orgCorticotropin Ag [Presence] in Tissue by Immune stain
10476-0 http://loinc.orgDesmin Ag [Presence] in Tissue by Immune stain
10477-8 http://loinc.orgEnolase.neuron specific Ag [Presence] in Tissue by Immune stain
10478-6 http://loinc.orgEosinophil major basic protein Ag [Presence] in Tissue by Immune stain
10479-4 http://loinc.orgCD227 Ag [Presence] in Tissue by Immune stain
1048-8 http://loinc.orgH NOS Ag [Presence] on Red Blood Cells from Blood product unit
10480-2 http://loinc.orgEstrogen+Progesterone receptor Ag [Presence] in Tissue by Immune stain
10481-0 http://loinc.orgFollitropin.alpha subunit Ag [Presence] in Tissue by Immune stain
10482-8 http://loinc.orgFollitropin.beta subunit Ag [Presence] in Tissue by Immune stain
10483-6 http://loinc.orgGastrin Ag [Presence] in Tissue by Immune stain
10484-4 http://loinc.orgGlial fibrillary acidic protein Ag [Presence] in Tissue by Immune stain
10485-1 http://loinc.orgGlucagon Ag [Presence] in Tissue by Immune stain
10486-9 http://loinc.orgHemoglobin Ag [Presence] in Tissue by Immune stain
10487-7 http://loinc.orgHMB-45 Ag [Presence] in Tissue by Immune stain
10488-5 http://loinc.orgIgA Ag [Presence] in Tissue by Immune stain
10489-3 http://loinc.orgIgA.heavy chain Ag [Presence] in Tissue by Immune stain
1049-6 http://loinc.orgH NOS Ag [Presence] on Red Blood Cells from donor
10490-1 http://loinc.orgIgE Ag [Presence] in Tissue by Immune stain
10491-9 http://loinc.orgIgG Ag [Presence] in Tissue by Immune stain
10492-7 http://loinc.orgIgG.heavy chain Ag [Presence] in Tissue by Immune stain
10493-5 http://loinc.orgIgM Ag [Presence] in Tissue by Immune stain
10494-3 http://loinc.orgIgM.heavy chain Ag [Presence] in Tissue by Immune stain
10495-0 http://loinc.orgInsulin Ag [Presence] in Tissue by Immune stain
10496-8 http://loinc.orgImmunoglobulin light chains.kappa Ag [Presence] in Tissue by Immune stain
10497-6 http://loinc.orgImmunoglobulin light chains.kappa amyloid Ag [Presence] in Tissue by Immune stain
10498-4 http://loinc.orgKeratin Ag [Presence] in Tissue by Immune stain
10499-2 http://loinc.orgImmunoglobulin light chains.lambda Ag [Presence] in Tissue by Immune stain
105-7 http://loinc.orgCeforanide [Susceptibility] by Disk diffusion (KB)
1050-4 http://loinc.orgH NOS Ag [Presence] on Red Blood Cells
10500-7 http://loinc.orgImmunoglobulin light chains.lambda amyloid Ag [Presence] in Tissue by Immune stain
10501-5 http://loinc.orgLutropin [Units/volume] in Serum or Plasma
10502-3 http://loinc.orgLutropin Ag [Presence] in Tissue by Immune stain
10503-1 http://loinc.orgLysozyme Ag [Presence] in Tissue by Immune stain
10504-9 http://loinc.orgMyelin basic protein Ag [Presence] in Tissue by Immune stain
10505-6 http://loinc.orgMyoglobin Ag [Presence] in Tissue by Immune stain
10506-4 http://loinc.orgPeanut agglutinin Ag [Presence] in Tissue by Immune stain
10507-2 http://loinc.orgProlactin Ag [Presence] in Tissue by Immune stain
10508-0 http://loinc.orgProstate specific Ag [Presence] in Tissue by Immune stain
10509-8 http://loinc.orgProstatic acid phosphatase Ag [Presence] in Tissue by Immune stain
1051-2 http://loinc.orgHemolytic disease of newborn screen [Interpretation] in Blood
10510-6 http://loinc.orgS-100 Ag Ag [Presence] in Tissue by Immune stain
10511-4 http://loinc.orgSerotonin Ag [Presence] in Tissue by Immune stain
10512-2 http://loinc.orgSomatostatin Ag [Presence] in Tissue by Immune stain
10513-0 http://loinc.orgSomatotropin Ag [Presence] in Tissue by Immune stain
10514-8 http://loinc.orgSynaptophysin Ag [Presence] in Tissue by Immune stain
10515-5 http://loinc.orgThyroglobulin Ag [Presence] in Tissue by Immune stain
10516-3 http://loinc.orgThyrotropin Ag [Presence] in Tissue by Immune stain
10517-1 http://loinc.orgTrypsin Ag [Presence] in Tissue by Immune stain
10518-9 http://loinc.orgUlex europaeus I lectin Ag [Presence] in Tissue by Immune stain
10519-7 http://loinc.orgVimentin Ag [Presence] in Tissue by Immune stain
1052-0 http://loinc.orgDeprecated I (intermediate) subtype [Presence] in Serum or Plasma from Blood product unit
10520-5 http://loinc.orgCoagulation factor VI Ag [Presence] in Tissue by Immune stain
10521-3 http://loinc.orgCoagulation factor VIII Ag [Presence] in Tissue by Immune stain
10522-1 http://loinc.orgCoagulation factor XIII Ag [Presence] in Tissue by Immune stain
10523-9 http://loinc.orgFibrinogen Ag [Presence] in Tissue by Immune stain
10524-7 http://loinc.orgMicroscopic observation [Identifier] in Cervix by Cyto stain
10525-4 http://loinc.orgMicroscopic observation [Identifier] in Unspecified specimen by Cyto stain
10526-2 http://loinc.orgMicroscopic observation [Identifier] in Sputum by Cyto stain
10527-0 http://loinc.orgMicroscopic observation [Identifier] in Tissue by Cyto stain
10528-8 http://loinc.orgAcetophenazine [Mass/volume] in Serum or Plasma
10529-6 http://loinc.orgAmoxapine metabolite [Mass/volume] in Serum or Plasma
1053-8 http://loinc.orgDeprecated I (intermediate) subtype [Presence] in serum or plasma from donor
10530-4 http://loinc.orgAprobarbital [Mass/volume] in Serum or Plasma
10531-2 http://loinc.orgBretylium [Mass/volume] in Serum or Plasma
10532-0 http://loinc.orgDeprecated Desethylamiodarone [Mass/volume] in Serum or Plasma
10533-8 http://loinc.orgPropoxyphene+Acetaminophen [Mass/volume] in Serum or Plasma
10534-6 http://loinc.orgDiazoxide [Mass/volume] in Serum or Plasma
10535-3 http://loinc.orgDigoxin [Mass/volume] in Serum or Plasma
10536-1 http://loinc.orgDipyridamole [Mass/volume] in Serum or Plasma
10537-9 http://loinc.orgDeprecated Doxepin+Nordoxepin [Mass/volume] in Serum or Plasma
10538-7 http://loinc.orgDeprecated Fluoxetine+Norfluoxetine [Mass/volume] in Serum or Plasma
10539-5 http://loinc.orgGlipizide [Mass/volume] in Serum or Plasma
1054-6 http://loinc.orgDeprecated I (intermediate) subtype [Presence] in srum
10540-3 http://loinc.orgGlyburide [Mass/volume] in Serum or Plasma
10541-1 http://loinc.orgMepivacaine [Mass/volume] in Serum or Plasma
10542-9 http://loinc.orgMetharbital [Mass/volume] in Serum or Plasma
10543-7 http://loinc.orgMethsuximide+Normethsuximide [Mass/volume] in Serum or Plasma
10544-5 http://loinc.orgNormeperidine [Presence] in Serum or Plasma
10545-2 http://loinc.orgNormephenytoin [Mass/volume] in Serum or Plasma
10546-0 http://loinc.orgNormethsuximide [Mass/volume] in Serum or Plasma
10547-8 http://loinc.orgPrimidone+Phenobarbital [Mass/volume] in Serum or Plasma
10548-6 http://loinc.orgPhenytoin Free/Phenytoin.total in Serum or Plasma
10549-4 http://loinc.orgPirmenol [Mass/volume] in Serum or Plasma
1055-3 http://loinc.orgDeprecated I (intermediate) subtype [Presence] on Red Blood Cells from Blood product unit
10550-2 http://loinc.orgDeprecated Temazepam [Mass/volume] in Serum or Plasma
10551-0 http://loinc.orgTriamterene [Mass/volume] in Serum or Plasma
10552-8 http://loinc.orgTricyclic antidepressants [Mass/volume] in Serum or Plasma
10553-6 http://loinc.orgProstatic acid phosphatase [Enzymatic activity/volume] in Genital fluid
10554-4 http://loinc.orgDeprecated Prostatic acid phosphatase [Enzymatic activity/volume] in Seminal plasma
10555-1 http://loinc.orgAcrosin [Entitic Catalytic Activity] in Spermatozoa
10556-9 http://loinc.orgDeprecated Adenosine triphosphatase [Enzymatic activity/volume] in Seminal plasma
10557-7 http://loinc.orgAdenosine triphosphate [Moles/volume] in Semen
10558-5 http://loinc.orgAlbumin [Moles/volume] in Semen
10559-3 http://loinc.orgDeprecated Calcium [Molecules/volume] in Semen
1056-1 http://loinc.orgDeprecated I (intermediate) subtype [Presence] on Red Blood Cells from donor
10560-1 http://loinc.orgCarcinoembryonic Ag [Units/volume] in Semen
10561-9 http://loinc.orgCarnitine [Moles/volume] in Semen
10562-7 http://loinc.orgCells [#/volume] in Cervical mucus
10563-5 http://loinc.orgCells other than spermatozoa [#/volume] in Semen
10564-3 http://loinc.orgCervical mucus [Volume]
10565-0 http://loinc.orgChoriogonadotropin [Units/volume] in Semen
10566-8 http://loinc.orgDeprecated Choriogonadotropin [Molecules/volume] in Semen
10567-6 http://loinc.orgCitrate [Moles/volume] in Semen
10568-4 http://loinc.orgClarity of Semen
10569-2 http://loinc.orgColor of Semen
1057-9 http://loinc.orgDeprecated I (intermediate) subtype [Presence] on Red Blood Cells
10570-0 http://loinc.orgConsistency of Cervical mucus
10571-8 http://loinc.orgDeprecated Consistency of Semen
10572-6 http://loinc.orgDeprecated Duration^post ejaculation
10573-4 http://loinc.orgFerning [Type] in Cervical mucus
10574-2 http://loinc.orgFructose [Moles/volume] in Semen
10575-9 http://loinc.orgDeprecated Gamma glutamyl transferase [Enzymatic activity/volume] in Semen
10576-7 http://loinc.orgGerm cells.immature [#/volume] in Semen
10577-5 http://loinc.orgGlucosidase [Enzymatic activity/volume] in Seminal plasma
10578-3 http://loinc.orgGlycerophosphocholine [Moles/volume] in Seminal plasma
10579-1 http://loinc.orgLeukocytes [#/volume] in Semen
1058-7 http://loinc.orgI Ab [Presence] in Serum or Plasma from Blood product unit
10580-9 http://loinc.orgLiquefaction [Time] in Semen
10581-7 http://loinc.orgDeprecated Number of entities [#] in Spermatozoa
10582-5 http://loinc.orgpH of Cervical mucus
10583-3 http://loinc.orgProstaglandin F1 alpha [Moles/volume] in Semen
10584-1 http://loinc.orgDeprecated Protein [Mass/volume] in Semen
10585-8 http://loinc.orgRound cells [#/volume] in Semen
10586-6 http://loinc.orgDeprecated Volume of Semen
10587-4 http://loinc.orgSexual abstinence duration
10588-2 http://loinc.orgSpermatogonia [#/volume] in Semen
10589-0 http://loinc.orgSpermatids [#/volume] in Semen by Streptoavidin-biotin method (SAB)
1059-5 http://loinc.orgI Ab [Presence] in Serum or Plasma from donor
10590-8 http://loinc.orgSpermatids [#/volume] in Semen by Sertoli cell barrier method (SCB)
10591-6 http://loinc.orgPrimary Spermatocytes [#/volume] in Semen
10592-4 http://loinc.orgSecondary Spermatocytes [#/volume] in Semen
10593-2 http://loinc.orgSpermatozoa Pyriform Head/100 spermatozoa in Semen
10594-0 http://loinc.orgSpermatozoa Tapering Head/100 spermatozoa in Semen
10595-7 http://loinc.orgDeprecated Spermatozoa [#/volume] in Semen
10596-5 http://loinc.orgDeprecated Spermatozoa Ab in cervical mucosa
10597-3 http://loinc.orgDeprecated Spermatozoa Ab in semen
10598-1 http://loinc.orgDeprecated Spermatozoa Ab in serum
10599-9 http://loinc.orgSpermatozoa penetration [Presence] in Seminal fluid and Cervical mucosa by Kremer test
106-5 http://loinc.orgCeforanide [Susceptibility] by Serum bactericidal titer
1060-3 http://loinc.orgI Ab [Presence] in Serum or Plasma
10600-5 http://loinc.orgSpermatozoa penetration [Presence] in Seminal fluid and Cervical mucosa
10601-3 http://loinc.orgSpermatozoa penetration [Presence] in Seminal fluid and Cervical mucosa --post coitus
10602-1 http://loinc.orgSpermatozoa Abnormal Head/100 spermatozoa in Semen
10603-9 http://loinc.orgSpermatozoa Abnormal Midpiece/100 spermatozoa in Semen
10604-7 http://loinc.orgSpermatozoa Abnormal Tail/100 spermatozoa in Semen
10605-4 http://loinc.orgSpermatozoa Agglutinated/100 spermatozoa in Semen
10606-2 http://loinc.orgSpermatozoa Amorphous Head/100 spermatozoa in Semen
10607-0 http://loinc.orgSpermatozoa Coiled Tail/100 spermatozoa in Semen
10608-8 http://loinc.orgSpermatozoa Cytoplasmic Droplet/100 spermatozoa in Semen
10609-6 http://loinc.orgSpermatozoa Duplicate Head/100 spermatozoa in Semen
1061-1 http://loinc.orgI NOS Ab [Presence] in Serum or Plasma from Blood product unit
10610-4 http://loinc.orgSpermatozoa Duplicate Tail/100 spermatozoa in Semen
10611-2 http://loinc.orgSpermatozoa Immotile/100 spermatozoa in Semen
10612-0 http://loinc.orgSpermatozoa Large Oval Head/100 spermatozoa in Semen
10613-8 http://loinc.orgSpermatozoa Viable/100 spermatozoa in Semen
10614-6 http://loinc.orgSpermatozoa Motile w IgA/100 spermatozoa in Semen by Immunobead
10615-3 http://loinc.orgSpermatozoa Motile w IgA/100 spermatozoa in Semen by Mixed antiglobulin reaction
10616-1 http://loinc.orgSpermatozoa Motile w IgG/100 spermatozoa in Semen by Immunobead
10617-9 http://loinc.orgSpermatozoa Motile w IgG/100 spermatozoa in Semen by Mixed antiglobulin reaction
10618-7 http://loinc.orgSpermatozoa Motile w IgM/100 spermatozoa in Semen by Immunobead
10619-5 http://loinc.orgSpermatozoa Motile w IgM/100 spermatozoa in Semen by Mixed antiglobulin reaction
1062-9 http://loinc.orgI NOS Ab [Presence] in Serum or Plasma from donor
10620-3 http://loinc.orgSpermatozoa Nonprogressive/100 spermatozoa in Semen
10621-1 http://loinc.orgSpermatozoa Normal Head/100 spermatozoa in Semen
10622-9 http://loinc.orgSpermatozoa Normal/100 spermatozoa in Semen
10623-7 http://loinc.orgSpermatozoa Pin Head/100 spermatozoa in Semen
10624-5 http://loinc.orgSpermatozoa Rapid/100 spermatozoa in Semen
10625-2 http://loinc.orgSpermatozoa Round Head/100 spermatozoa in Semen
10626-0 http://loinc.orgSpermatozoa Slow/100 spermatozoa in Semen
10627-8 http://loinc.orgSpermatozoa Small Oval Head/100 spermatozoa in Semen
10628-6 http://loinc.orgSpermatozoa Tail Swelling/100 spermatozoa in Semen
10629-4 http://loinc.orgSpermatozoa Vacuolated Head/100 spermatozoa in Semen
1063-7 http://loinc.orgI NOS Ab [Presence] in Serum or Plasma
10630-2 http://loinc.orgSpinnbarkeit [Length] in Cervical mucus
10631-0 http://loinc.orgTestosterone [Moles/volume] in Semen
10632-8 http://loinc.orgTime until next menstrual period
10633-6 http://loinc.orgZinc [Moles/volume] in Semen
10634-4 http://loinc.orgComplement C1 esterase inhibitor.functional/Complement C1 esterase inhibitor.total in Serum or Plasma
10635-1 http://loinc.orgAcanthamoeba sp identified in Eye by Organism specific culture
10636-9 http://loinc.orgAcanthamoeba sp identified in Eye by Wet preparation
10637-7 http://loinc.orgMicroscopic observation [Identifier] in Tissue by Night blue stain
10638-5 http://loinc.orgThermophilic Actinomycetes colony count [#/volume] in Unspecified specimen by Organism specific culture
10639-3 http://loinc.orgThermophilic Actinomycetes identified in Unspecified specimen by Organism specific culture
1064-5 http://loinc.orgI NOS Ag [Presence] on Red Blood Cells from Blood product unit
10640-1 http://loinc.orgDeprecated Adenovirus 40+41 [Identifier] in Stool by Electron microscopy
10641-9 http://loinc.orgAmoeba identified in Aspirate by Immune stain
10642-7 http://loinc.orgAmoeba identified in Aspirate by Wet preparation
10643-5 http://loinc.orgAmoeba identified in Stool by Organism specific culture
10644-3 http://loinc.orgArthropod identified in Unspecified specimen
10645-0 http://loinc.orgAspergillus fumigatus Ag [Presence] in Tissue by Immunofluorescence
10646-8 http://loinc.orgAstrovirus [Identifier] in Stool by Electron microscopy
10647-6 http://loinc.orgBabesia sp identified in Blood by Thick film
10648-4 http://loinc.orgBabesia sp identified in Blood by Thin film
10649-2 http://loinc.orgCalicivirus [Identifier] in Stool by Electron microscopy
1065-2 http://loinc.orgI NOS Ag [Presence] on Red Blood Cells from donor
10650-0 http://loinc.orgCandida sp DNA [Presence] in Blood by Probe with amplification
10651-8 http://loinc.orgChlamydophila pneumoniae Ag [Presence] in Sputum or Bronchial